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INTRODUCTION 
Siddha system of medicine is the traditional medical system of India which 
has flourished well before many centuries. Siddha is practiced till now rather than 
other traditional medical systems.  In the wake of changing mode of life and modern 
medicine, Siddha continues to sustain its influence because of its incomparable 
intrinsic merits. This system was originated by siddhars with their holistic spiritual 
powers. 
 
Agathiyar, Thirumoolar, Bogar, Theraiyar, Pulippani are the most remarkable 
siddhars. Agathiyar was the top most siddhar who is regarded as the originator of the 
Siddha medicine and also the Tamil Language. Siddhars are specialized in 
Vaatham,Vaithiyam, Yogam, Gnanam which helps to attain spirituality through 
prevent the body from disease, increase the lifespan by rejuvenation. 
 
In India, five types of landscapes such as Kurinji, Mullai, Marutham, Neithal, 
Paalai contains many herbs helps to cure the disease of the people living there. 
Innumerable varieties of herbs, metals and minerals are mentioned in siddha 
literatures. 
 
Siddha medicines are classified into Internal medicine thirty two types and 
External medicine thirty two types. The internal medicine starts as a simple 
preparations like saaru, kudineer, chooranam and ends in higher order medicines like  
kattu, kalangu, chunnam, Theeneer, chendhuram etc,. 
 
Siddhars are alchemist who used metals and minerals in drugs for therapeutic 
effect. Mercury and other minerals are generally a poison for uninitiated but for the 
siddhars who knows how to detoxify it and pulverize it to nano ions, it is the nector of 
immortality. Chendhuram is one type of these internal medicine in siddha which is 
metallic substances or arsenical compounds are made into red coloured powders by 
the process of burning, frying or insulating or keeping them in specialized pudams  by 
grinding them with decoctions, ceyaneer juices etc. 
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The size of particles present in higher order medicine are in nano level at the 
end of the process. So nano technology is the prime tool for siddha herbo-mineral 
drugs in which the medicine targets the affected spot and cures the disease. Nano 
medicines like chendhuram will scale down the number of doses and increases the bio 
availability. Siddha nano medicines will cure many chronic diseases with minimal 
side effects and with minimal drug dose which baffles and eludes even the modern 
sophisticated medicine. 
 
Vitiligo is an acquired, idiopathic, depigmentory condition of skin and hair 
varying sizes and shapes. It affecting people of all ages and both sexes equally. 
Patients lose their skin color mostly in patchy and progressive manner. 
 
The cause is still under debate. Although there are rarely physical symptoms 
involved many patients experience stigmatization, unwanted attention, negative 
comments, rejection or bullying. The prevalence of vitiligo is often said to range from 
0.09 to 8% especially in India. 
 
 There are lot of drugs in our siddha system for Vitiligo. For the study, I 
selected the Rasa Chendhuram as internal medicine and Palagarai Kuzhambu as 
external medicine in the management of Vitiligo both in preclinical as well as clinical 
aspect. 
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AIM AND OBJECTIVES 
AIM: 
To evaluate the Siddha Drug Rasa Chendhuram (internal) and Palagarai 
Kuzhambu (external) in the management of Vitiligo. 
 
OBJECTIVES: 
Primary objective: 
            To evaluate the therapeutic efficacy of the siddha drug Rasa Chendhuram 
(Internal) and Palagarai Kuzhambu (External) in Venpulli (Vitiligo). 
 
Secondary objectives: 
 To study the safety profile of trial drug Rasa Chendhuram (Internal). 
 The main objective of this study is to add the scientific evidences to 
Siddhars work which in turn create awareness among the public. 
 To discuss the various literature evidences of Venpulli in Siddha 
Medicine and Vitiligo in modern science. 
 To correlate the clinical features of Venpulli in Siddha medicine with 
Vitiligo in modern science. 
 To correlate the modern purification method and siddha purification 
method of raw drugs.  
  To get the authentication of the raw drug. 
 To standardize the standard operating procedure. 
 To study the Physico - Chemical analysis of the selected trial drug. 
 To study the acute & sub acute toxicity of the trial drug Rasa 
Chendhuram according to OECD guidelines. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
Synonyms: 
Venkuttam 
Swetha Kuttam 
Venthittu 
Venpadai 
Definition : 
Venpulli is defined as the discoloration of the skin characterized by the appearance of the 
white patches in irregular shape of the epidermis of the skin and sometimes hair also involved. 
 
In siddha system venpulli is considered as one of the eighteen kinds of kuttam. Siddhar 
Yugimuni mentioned this condition as Suvetha Kuttam in “Yugimuni Vaithiya Chinthamani – 
800”. 
 
தடிப்பாக தவள நிறம் பபால் வவளுத்துச் 
சர்வாங்கமும் வவளுத்தாற் றான்றிரும்பும் 
மடிப்பாக மயிர்வவளுத்தா லசாத்ய மாகும் 
வரிவுதடு வுள்ளங்கக குதங்குய்யந்தான் 
வநடிப்பாக வநருப்பு பட்டது பபால புண்ணாய் 
நிறமிருந்தா லசாத்தியவமன்பற யுகைக்கலாகும்  
வவடிப்பாக பமனிவயல்லாம் வவளுத்து வஙீ்கி  
வவண்சுபவத குட்டவமன்பற விளம்பலாபம. 
  
 Hypopigmented patches all over the body. 
 Hypopigmentation on hair, lips, palm, sole, anus and pubic region –incurable. 
 If  the lesion is like burnt scar- incurable. 
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பநாய் வரும் வழி: (Aetiology) 
 
         According to siddha system, the predisposing causes for this diseases have been described 
as hereditary factor, stress and strain, malnutrition and venereal exposure and no other specific 
causes have been mentioned for venpulli.   
1) According to Agathiyar Kanma Kandam 
“பசர்ந்தகுட்ட பமாடுகுகற பநாய்கள் வந்த 
பசதிகள் மலைாதவரும்பு வகாய்தல் 
தாரிந்த சவீவசந்து வகதகள் வசய்தல் 
தாய் தந்கத மனதுவநாந்தது பைாகந்தாபன“ 
தாவனன்ற வதய்வவுருத் தகனயழித்தல் 
சார்வான வபரிபயார்கள் தகமப் பழித்தல் 
காவனன்ற நந்தவனம் பூஞ்வசடிகள் வவட்டல் 
கருமமடா சரீைத்திற் காசு பபாபல 
யூவனன்ற வுடம்வபல்லாம் வமாட்டுப் வபாட்டா 
யுடன் வவளுத்து குகறபநாயா யுதிைஞ்சிந்தும் 
வாவனன்ற கருமங்கள் தரீ்ப்பதற்கு 
வககவயான்று வசால்பவன் பகள் நந்தவனம்கவபய 
 
அகத்தியர் கன்ம காண்டம் வகௌமதி நூல் பக்கம் – 27 
 
           Agathiyar kanmakandam  says  that  picking  flowers before blossoming,  killing living 
creature, giving sorrow to the parents, destroying temples, abusing noble person, cutting plants 
cause Venpulli noi. 
 
2) According to Thirumoolar Karukkidai Vaithya Nool   
 
“வியாதியுண் மூவாறு விளங்கிய குட்டங்பகள் 
சுயாதிக் கிைந்தி சுழன் பமகத்தாலாறும் 
பயாதி மண்ணுளப் பலவண்டினா வலட்டும் 
நியாதிப் புழுநாலாய் நின்றதிக் குட்டபம.” 
 
                  Six types of kuttam i.e, skin diseases are caused by kiranthi and megam, eight types 
are caused by insects in the soil, and four types are caused by worms.    
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3) According to Dhanvanthri vaidhyam 
“அறிவின்றி விபரிதஞ் பசைாகாைம் புசிக்கலாலும் 
துகறயன்றி வதாடாத வதான்கற வதாட்டகவப் புசிக்கலாலும் 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 
வந்திந்துப் பூருவா வசன் மாந்திை பாவத்தாலுஞ் 
சந்திக்கக் கற்புமாதர் தங்ககளக் கருதலாலும் 
வதாந்தித்த குட்டபைாகந் வதாடுக்குவமன்றுகைத்தார் முன்பனார்.”  
 
4) According to Dhanvanthiri Vaidhyam 
 Intake of unhygienic food 
 Abusing the elderly people like Siddhars and saints. 
 Blaming the worshipping ladies. 
 Sins committed in the previous birth. 
 Thinking of seducing chaste women. These are   the causes mentioned by 
Dhanvanthiri. 
 
5) According to “Guru Naadi Nool’’ 
“கிருமியால் வந்தபதாடம் வபருக வுண்டு 
பகட்கவதின் பிரிவதகனக் கிைம மாக 
வபாருமிவரும் வாயுவவல்லாம் கிருமி யாபல 
புழுக்கடி பபால் காணுமது கிருமியாபல 
வசருமிவரும் பவுத்திைங்கள் கிருமியாபல 
பதகமதில் பசாககக்குட்டங் கிருமியாபல 
துருமிவருஞ் சுபைாணிதங் கிருமியாபல 
சூட்சமுடன் கிரிகசப்பால் வதாழில்வசய் வபீை”. 
 
கிருமியால் உண்டாகும் குட்டம் வைலாறு8 
“குட்டமது விடகைப்பான் விடநீர் சூகல 
சுபைாணிதத்தால் தாதுவகட்டுத் தடிப்புண்டாகும் 
மட்டறபம கிருமிவசன்று மருவும் பபாது  
வககயாய்க் கிருமியுட விடநீர் வசன்று 
குட்டமுடன் பதகவமல்லாம் பறக்கும் பபாது 
குழிகுழியாய்க் கிருமியினகீ் வகாள்ளும் புள்ளி 
தட்டறபவ கிருமியுட நீைால்வந்த 
சகலகுட்டம் விடகைப்பான் சாற்ற லாபம.” 
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5) According to “Siddha Maruthuvam Sirappu” 
The etiology and the characters of Venpulli are clearly explained in the text “Siddha 
Maruthuvam Sirappu” as follows: 
In the affected area, reduction or total loss of skin pigment melanin on the epidermis is 
observed. As the distinct aetiology is not known, there exist certain beliefs and hypothesis about 
the disease. They are 
 Constant irritation to the skin owing to clothes, rubber, plastics or other chemical 
substances. 
 Some essential metal or mineral deficiency in the food 
 
6. According to “Eighteen Siddhars Naadi Nool” 
Excessive intake of acidic food stuffs leads to pallor and discolouration of skin are the 
cause for vitiligo said by Pathinen Siddhar Naadi Nool. 
 
7. According to “Agathiyar Vaithyam” 
குயல்வாய் குஷ்டம் சயங்குன்ம நீரிழிவு சுைக்கிைாணி 
நீைகடப்பு பாண்டு மூல வாய்வு  
கயல் வாயு வருங்கண்ணில் குத்தாய் கடிந்த தசவாய்வு 
காணவாக முன் வசய்த உயிர்களும் விகனதாபன 
Kuttam may be hereditary, apart from all other etiological factors Kuttam is also 
considered to be followed by Sins committed in the previous birth (Kanma vinai). 
 
CLASSIFICATION: 
1) According to yugi vaithiya chinthamani: 
 In “Yugimuni Vaithiya Chinthamani – 800”, Kuttam is classified into eighteen 
types. Swetha Kuttam (Venpulli) is one among them. It is mentioned as below: 
“முத்தாகும் குட்டந்தான் பதிவனட்டுக்கும்  
முனியான யூகினான் வசால்லக் பகளாய்  
புத்தாகும் புண்டரீக குஷ்டத்வதாடு 
வபருகின்ற விற்பபாடகக் குட்டமாகும் 
பத்தாகும் பாமா குஷ்ட ஏகசர்ம குஷ்டம் 
பரிவான கர்னகுஷ்டம் சர்மகுஷ்டம் 
கித்தாகுங் கிருஷ்ண குட்டம் அவுதும்பை குட்டம் 
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பகடியான மண்டல குஷ்டமாகு வமன்பன 
குட்டமா மபரிச குஷ்ட பமாடு 
மருவலாங் கிடீப குஷ்டந் சர்மதல குஷ்டந் 
திட்டமாற் தத்துரு குஷ்ட பமாடு 
தக்கான சித்துமா குஷ்டஞ் சதாரு குஷ்டந் 
துட்டமாஞ் சுபவத குஷ்டதன் பனாவடாக்கச் 
சுயம்பான  பதிவனட்டு குட்டமாச்பச. 
                                              (Page No:191) 
1.Pundareeka Kuttam  
2.Virpodaka Kuttam 
3.Baama Kuttam 
4.Gaja Saruma Kuttam 
5.Karna Kuttam 
6.Siguram 
7.Krishna Kuttam 
8.Avudhumbaram 
9.Mandala Kuttam 
10.Abarisa Kuttam 
11.Visarchika Kuttam 
12.Vibaathika Kuttam 
 13.Kideeba Kuttam 
14.Sarmathala Kuttam 
15.Thethru Kuttam 
16.Sithumaa Kuttam 
17.Sathaaru Kuttam 
18.Swetha Kuttam  
 
2) According to “siddha  maruthuvam sirappu” 
Venpadai  has been classified into four types : 
1.vaatha venpadai  
2.piththa venpadai 
3.kabha venpadai 
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3) According to athma rakshamirtha vaidhya sarasankiraham 
Kuttam is classified into 4 types 
1. Venkuttam 
2. Senkuttam 
3. Karunkuttam  
4. Peru viyathi 
 
4) According to “Pararasa Sekaram” 
Kuttam is classified into 5 types: 
1. Venkuttam 
2. Senkuttam 
3. Karunkuttam 
4. Vishakuttam 
5. Azhukannikuttam 
 
5) A classical work “Madhava Nithanam” classifies Venpulli noi as 
1. Savithram 
2. Kilesam 
3. Varunam 
  
6) According to siddhar aruvai  maruthuvam 
      Venpadai  has been classified into 3 types on the basis of mukkutram, they are, 
1. Vaatha venpadai  
2. Piththa venpadai  
 
CLINICAL FEATURES : 
 
1) According to “Yugimuni Vaithiya Chinthamani – 800” 
Yugimuni  attributed the Venpulli under the headline of Swetha Kuttam which is one 
of the eighteen kuttams and he mentioned the clinical features of swetha kuttam as below: 
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தடிப்பாக தவள நிறம் பபால் வவளுத்துச் 
சர்வாங்கமும் வவளுத்தாற் றான்றிரும்பும் 
மடிப்பாக மயிர்வவளுத்தா லசாத்ய மாகும் 
வரிவுதடு வுள்ளங்கக குதங்குய்யந்தான் 
வநடிப்பாக வநருப்பு பட்டது பபால புண்ணாய் 
நிறமிருந்தா லசாத்தியவமன்பற யுகைக்கலாகும்  
வவடிப்பாக பமனிவயல்லாம் வவளுத்து வஙீ்கி  
வவண்சுபவத குட்டவமன்பற விளம்பலாபம. 
 
Yugimuni gives a clear definition of Venpulli and he mentioned the conditions 
which will not responded to treatment (Asathiyam) as said below: 
1.   Whitish discoloration of the part of the body or entire body. Sometimes hair also 
turns white. 
2.   When white patches occur on the palms or muco-cutaneous junctions like lips, 
anus and genitals, it is said to be rarely curable. 
3.   If the hair becomes white, prognosis will be very bad. 
4.   Fissured body becomes oedematous. 
 
2) According to thanvanthiri vaithiyam  
 மீக்வகௌத் பதாறூவமலுபமார் முகம் வவளுக்குமாகில் 
பநாக்கியல் மரிக்குஞ் வசான்ன வவண்குட்டமாபம. 
When the colour of the face becomes white, it is called Venkuttam. 
 
3) According to Vaithya Sarasangiragam 
Sole, hands, lips, scalp, fingers and wrist joint all these organs are found with white 
coloured patches which are circumscribed along  with  thickened border and gradually spread  
which is known as venpulli . blood, muscle and  adipose tissue are affected by disease.  
 
Discolouration of hairs, absence of normal skin texture when compared with the 
adjoining normal skin area and appearance of burn scar is incurable. 
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Premonitory symptoms: 
1.   The skin appears glittering and rough 
2.   There is an excessive perspiration or no perspiration 
3.   Discoloration 
4.   Heat and itching of the skin 
5. Numbness in some parts of the body. 
 
4) According to Pararasa Sekaram 
1.   Watery discharge 
2.   Grey colour 
        3.   Foul smelling 
        4.   Dryness of the scalp 
 
5) A classical work “Madhava Nithanam” classifies Venpadai as 
 Savithram – venpulli affecting muscular tissue. 
 Kilesam     - venpulli affecting the skin. 
 Varunam   - venpulli affecting the adipose tissue.     
These types are not having any pathological discharge. 
 
Kilesam is classified on the basis of mukkutram and their features are as follows: 
 Vaatha kilesam           - Reddish white in colour. 
 Piththa kilesam           - Red coloured patches resembling the petal colour of lotus. 
 Kaba kilesam              - milky thickened white patches with itching. 
 
6)  According to anubhava vaithiya deva ragasiyam 
இந்பநாகய குஷ்டவமன கூறினும் இது குஷ்ட வகககளின்று பவறுபட்டது 
என்பகதயும் குஷ்டத்கதப் பபால் அவ்வளவு வகாடுகமயான வியாதி அல்லவவன்றும் 
உணைபவண்டும். இந்பநாயில் திட்டு திட்டாக வவண்கம நிறமான பகடகள் உண்டாகி 
பிறகு பதகம் முழுவதும் பைவி உடகல விகாைப்படுத்துதல் முதலிய குணங்ககள 
உகடயது. 
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Three types 
1. Vatha  venpadai 
2. Piththa  venpadai 
3. Kaba  venpadai 
 
CLINICAL FEATURES 
1. The skin appears glittering and rough 
2. There is an excessive perspiration  
3. Discolouration 
4. Heat and itching of the skin 
5. Numbness in some parts of the body 
 
According to Sirappu Maruthuvam 
1. Vaatha  Venpadai 
2. Piththa  Venpadai  
3. Kaba  Venpadai 
4. Mega  Venpadai 
 
1. VAATHA VENPADAI 
 It is characterized by the presence depigmented  patches ,which are dry ,rough, reddish or  
pale black in colour. 
 
2. PITHA VENPADAI 
It is characterized by the presence of   depigmented patches which are red in colour like 
lotus flower, spreading with burning sensation and loss of hairs on that area. 
 
3. KABA VENPADAI  
 It is characterized by the depigmented patches which are white in colour like leucas 
flower spreads with rashes and itching . 
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4. MEGA VENPADAI  
 It is due to the veneral disease and it occurs after 4 or 6 months after the onset of disease, 
syphilis within four or six months of the attack. This venpadai develops initially along the nape 
and the adjoining spaces. Also gradually it affects the  shoulder joints, back of trunk . 
 
Clinical features of this type  
Depigmented patches are small in number. Pale in colour, turmeric colour or dark colour margin 
marked with hyperpigmented signs. These lesion are circumscribed with 2mm to 3mm diameter 
or above. This correct picture of hypopigmented and hyper pigmented skin seems to be more or 
less a multi eyed filter (sieve–like) Females are more prone to this mega venpadai, therefore anti 
–syphilitic  therapy  is mandatory in the early period of the treatment. 
 
CHARACTER OF VENPADAI 
Skin color will change to reddish black or reddish white or white colour with spreading 
nature. The imbalance of the three thathu produces certain lesions in skin known as kuttam. 
Absence of perspiration and thickening of skin may produce the colour changes in skin. 
 
தரீும், தைீாதகவ 
1) ACCORDING TO DHANVANTHIRI VAITHYAM 
சாத்தியம்-11 
பூண்டந் நுைவிபனாடு சதாரிகம் புண்டரீ கந்த 
தாண்டு விற்பபாடம் பாமாவுடன்கமதலம் வவண்குட்டம் 
கூண்டிடு காகறந்தி சிறுகம யசல குட்டம்  
பவண்டியவியாதிபயாடும் பதிவனான்றும் விரித்துக் காபன.  (Page No  :  325) 
 
அசாத்தியம் 
வசால்லுகுட்டம்  ஏழுவககபபர் வசால்லிக் கபால சர்மீகம் 
வவல்லு முதும்பா பமகிடிபம் விசர்ச்சிமண்டலக் கிைமும் 
மல்லல் தருமீசி யகுகவ யாகும் வபயபைா ழாகும் 
வல்லகியாதிக் குணமதகன வகுத்துப் பாரிலுகைகைப்பபபன”  
    
  
14 
 
CURABLE-11 
1. Thethru Kuttam 
2. Sadhaaru Kuttam  
3. Pundareega Kuttam  
4. Virpodaga Kuttam  
5. Sarmathala Kuttam  
6. Baama Kuttam  
7. Kaha Nandhi 
8. Venkuttam 
9. Sithuma Kuttam 
10. Alasa Kuttam 
11. Vibaathiga Kuttam 
 
INCURABLE -7 
1. Kabaala kuttam 
2. Sarumamega kuttam  
3. Kideeba kuttam  
4. Avudhumbara kuttam  
5. Visarchika kuttam 
6. Aguvai kuttam  
7. Mandala kuttam  
 
ACCORDING TO  YUGI CHINTHAMANI-800 
குட்டந்தான் பதிவனட்டில் சாத்தியந்தான் 
கூறக்பகள் விற்பபாடக பாமா குட்டம்  
திட்டந்தான் வகசசர்ம குட்டவமாடு 
கிருட்டிண குட்டமவுதும்பை குட்டந்தானும் 
திட்டமாந் பதத்துருக் குட்டவமாடு 
வசய்சித்துமா குட்டங் கிடிப குட்டம் 
தட்டந்தான் மிகுந்தச தாரு குட்டம்  
சமகிருட்டிண குட்டம்சாத் தியமா வமன்பன”  (Page No:200) 
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CURABLE  
1. Virpodagam kuttam  
2. Baama kuttam 
3. Gaja Saruma kuttam 
4. Krishna kuttam  
5. Avuthumbara kuttam 
6. Thethuru kuttam 
7. Sithuma kuttam 
8. Kideepa kuttam 
9. Sathaaru kuttam 
10. Sarmathala kuttam 
 
INCURABLE  
1. Pundareeka kuttam 
2. Karna kuttam 
3. Sikura kuttam 
4. Mandala kuttam 
5. Abarisa kuttam 
6. Visarchika kuttam 
7. Swetha kuttam 
8. Vibathika kuttam . 
 
2) According to the text “Siddha Maruthuvam Sirappu” 
Curable conditions in Venpulli are: 
Lesions without any change in hair colour. 
Lesions without coarse texture. 
Lesions that are not appearing like white burnt scar.  
 
Uncurable conditions in Venpulli are: 
Lesions with whitened hair. 
Lesions feeling rough. 
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Lesion appearing like white burnt scar. 
If the lesion first appears on genitalia, anus palms and lips. 
Lesions of fast spreading nature. 
 
SIDDHA PATHOLOGY: 
  Disease occurs due to the derangement in 
 muththathukkal 
 seven Udal thathukkal 
 Kaala marupadukal (seasonal changes) 
 Thinai (living lands) and 
 Udal vanmai. 
 
Muththathukkal 
The function of the three uyir thathus: 
a) Vali     – Kattru + Veli 
b) Azhal – Thee  
c) Iyyam – Neer + Mann 
 
The alteration of three thathu in their reaction to extrinsic or intrinsic factors results in 
disharmony. This altered harmony and balance variation of the three thathus results in disease. 
Their natural ratio (1:1/2:1/4) to each other is discerned by the physician at the wrist and each 
nadi is individually assessed for its strength, speed and regularity. 
 
VATHAM 
The term vatham denotes vayu, dryness, pain and flatulence , sensitiveness, lightness and 
also air. Based on functions and locations it is classified into ten types.  
 
1. Piranan  
(Uyirkkaal) 
 Responsible for respiration and it is necessary for proper digestion.  
In venpulli noi  pranan is normal. 
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Abanan (Keel nokkukkaal) 
 Responsible for all the downward forces such as voiding of urine, stools, semen, menstrual flow. 
In venpulli noi abanan is normal. 
 
Viyanan(Paravukaal)  
Dwells in the skin and is concerned with the sense of touch, extension and flexion of the parts of 
the body and distribution of the nutrients to various parts of the body.  
In venpulli noi viyanan affected. (skin color changed into white). 
 
Uthanan (Melnokkukaal)  
Responsible for all kinds of upward motion such as nausea, vomiting etc., 
In venpulli noi uthanan is normal. 
 
Samanan(Nadukkaal)  
Considered essential for proper digestion, assimilation and carries the digested nutrients to each 
and every organ. 
 In venpulli noi samanan is normal. 
 
Nagan  
Helps in opening and closing of eyelids. 
 In venpulli noi nagan is normal. 
 
Koorman  
 Responsible for vision, lacrimation and yawning. 
 In venpulli noi koorman is normal. 
 
Kirugaran  
Induces appetite, salivation, all secretions in the body including nasal secretion and sneezing. 
In venpulli noi kirugaran is normal. 
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Thevathaththan 
 Induces and stimulates a person to become alert, get anger, to quarrel, to sleep etc., 
 In venpulli noi thevathathan is normal. 
 
Dhananjeyan  
Resides in the cranium and produces bloating of the body after death. This leaves from the body 
after 3 days of death, forming a way through the skull. 
In venpulli noi dhananjeyan is normal. 
 
PITHAM  
It is the thermal life force of the body. It is sub divided into five types. They are 
Anarpitham 
 
Peps up the appetite and aids in digestion.  
In venpulli noi anarpitham is normal. 
 
Ranjagapitham 
 Responsible for the colour and contents of blood. 
Ranjaga pitham affected in venpulli noi. 
 
 Saathagapitham 
 Controls the whole body and is held responsible for fulfilling a purpose.  
In venpulli noi saathaga pitham is normal. 
 
Pirasagapitham  
Dwells in the skin and concerned with the shine, glow, texture and its complexion. 
 In venpulli noi prasaga pitham is affected. 
 
Alosagapitham 
 Responsible for the perception of vision. In venpulli noi alosaga pitham is normal. 
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 KABAM 
 It is responsible for the stream line functions of the body and maintains body’s defence 
mechanism intact. It is again classified into 5 types. 
 
 Avalambagam 
 Lies in the respiratory organs, exercises authority over other kabhas and control the heart and 
circulatory system. 
 In venpulli noi avalambagam is normal. 
 
Kilethagam 
Found in stomach as it seat, moistens the food, softens and helps to be digested.  
In venpulli noi kilethagam is normal. 
 
Pothagam 
Responsible for the perception of taste. 
 In venpulli noi pothagam is normal. 
 
Tharpagam 
Presents in the head and is responsible for the coolness of the eyes, sometimes may be referred to 
as cerebrospinal fluid. 
In venpulli noi tharpagam is normal. 
 
Santhigam  
Necessary for the lubrication and the free movements of joints .  
In venpulli noi santhigam is normal. 
 
PARUVAKALAM  MAARUBADUKAL : 
With reference to the position of the sun in the orbit, the years divided into six seasons . 
They are, 
Perum pozhuthugal 
1) Kaar kaalam 
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(Aavani & Purattasi) 
Mid August to Mid October  
Mukkutra marupaadugal 
VATHAM - Vaetrunilai valarchi 
PITHAM – Thannilai valarchi   
 
Perum pozhuthugal 
2) Koothir kaalam 
(Iypasi & Karthigai) 
Mid October to Mid December  
VATHAM – Thannilai adaidhal 
PITHAM - Vaetrunilai valarchi  
 
Perum pozhuthugal 
3)Munpani kaalam 
(Margazhi & Thai) 
Mid December to Mid February  
PITHAM – Thannilai adaidhal  
 
Perum pozhuthugal 
4)Pinpani kaalam 
(Masi & Panguni) 
Mid February to Mid June 
KABHAM – Thannilai valarchi  
 
Perum pozhuthugal 
5)Elavenir kaalam 
(Chithirai & Vaikaasi) 
Mid April to Mid June 
 KABHAM – Vaetrunilai valarchi 
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 Perum pozhuthugal 
6) Mudhuvenir kaalam 
(Aani & Aadi) 
Mid June to Mid August 
VATHAM – Thannilai valarchi 
KABHAM – Thannilai adaidhal  
 
In every season there will be changes in the land, water, plants, animals and human 
beings , which will modify the physiology and making (rendering) them susceptible to certain 
specific disease which are common in these seasons. The siddhars have been anticipated those 
changes and advised certain measures in the form of diet, purgative, etc  
 
THINAI (LAND) 
  Siddhars classified the lands into five types. They are  
1. Kurunji – Mountain range 
2. Mullai – Pastoral area of the forest 
3. Marudham – The fertile river bed 
4. Neidhal – The coastal region 
5. Paalai – Arid desert 
 
 Kabha diseases will occur in Kurinji land. Pitha diseases occur in Mullai land. Vadha 
diseases occur in Neidhal land. Staying in Paalai land is not good to health. Marudham 
land is the fertile area where no disease occurs. So, Marudham land is the best one to stay 
in. 
        The winter season gives good health to the man, early summer and later rainy gives 
moderate health. Whereas early rainy and later summer are more prone to diseases,  that’s why 
siddhars called it as Aanadha kaalam. 
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 RELATION BETWEEN MUKKUTRAM, KAALANGAL AND THINAIGAL 
 
 
Mukkutram 
Paruvakaalam (Seasons)  
 
Thinai 
Thannilai 
valarchi 
(Accumulation) 
Vaetrunilai 
valarchi 
(Aggravation) 
Thannilai 
adaidhal 
(Alleviation) 
VATHAM Mudhuvenil 
kaalam 
Kaar kaalam Koothir kaalam Vatha disease is 
more prevalent in 
Neidhal land  
PITHAM Kaar kaalam Koothir kaalam Munpani kaalam Pitha disease is 
more prevalent in 
Mullai land 
KABHAM Pinpani kaalam Elavenil kaalam Mudhuvenil 
kaalam 
Kabha disease is 
more prevalent in 
Kurunji land 
 
UDAL VANMAI (IMMUNITY) 
 Siddhars classify udal vanmai into three types. They are 
1. Iyarkai vanmai 
2. Kala vanmai 
3. Seyarkai vanmai 
 
UDAL KATTUGAL 
S.No Udal kattugal General Features Changes in 
venpulli 
1 Saaram 
 (Digestive essence) 
Responsible for the growth and 
development. It keeps the individual in 
good temperament and it enriches the body. 
affected 
2 Senneer (Blood) Responsible for the color of the blood and 
for the intellect, nourishment, strength of 
the body. 
Affected 
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3 Oon (Muscle) Gives lookable contour to the body as 
needed for the physical activity. It feed the 
fat next day and gives a sort of plumpness 
to the body. 
Normal 
4 Kozhuppu (Fat) Lubricates the organs to facilitate 
frictionless functions. 
Normal 
5 Enbu (Bones) Supports and protects the vital organs, 
gives the definite structure of the body and 
responsible for the posture and movements 
of the body. 
Normal 
6 Moolai (Bone marrow) Nourishes the bone marrow and brain 
which is the centre that controls other 
system of body. 
Normal 
7 Sukkilam/Suronitham 
(Sperm/Ova) 
Responsible for reproduction30. Normal 
 
PINIYARI MURAIMAI (DIAGNOSIS) 
Four steps are followed in diagnosing the disease. They are 
1. Poriyaal aridhal 
2. Pulanal therdhal 
3. Vinaadhal 
4. Envagai thervugal 
 
PORIYAAL ARIDHAL: 
 In this, the physician should carefully observe the changes that occur in the five sensory 
organs (porigal) of the patient. 
 
PULANAL THERDHAL: 
 The physician carefully applies his five senses of perception, smell, taste, vision, touch 
and sound to understand the condition of the patient. 
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VINAADHAL: 
 The physician should interrogate about the patients name, age, occupation, socio- 
economic status, food habits, history of past illness, history of present illness, family history, 
marital status, menstrual history and frequency of pain. 
 
ENVAGAI THERVUGAL: 
நாடிப்பரிசம் நாநிறம் வமாழிவிழி 
மலம் மூத்திைமிகவ மருத்துவைாயுதம் 
                                                             noi nadal noi mudhal nadal thirattu, part-i (pg no-270)  
           Nowadays advanced diagnostic tools have been developed by modern bio medical 
scientists. But siddhars have given eight diagnostic methodological tools. They are called as 
Envagai thervu. 
 
Eight fold system of clinical assessments: 
 Siddhars have given eight diagnostic methodological tools. They are 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
 
GENERAL FINDINGS: 
NAADI: 
 Naadi is responsible for the existence of life, can be felt one inch below the wrist on the 
radial side by means of palpation with tips of index, middle and ring finger, corresponding to 
vatham, pitham, kabham. 
 Three humours Vatham, Pitham, and Kabham are in the ratio 1:1/2:1/4 normally. 
Derangement in these ratio leads to various disease conditions. 
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Naadi  in venpulli 
 Vathapitham or pitha kabam 
SPARISAM: 
 By sparisam, the temperature of skin (thatpam- cold or veppam – heat), smoothness, 
roughness, sweating, dryness, hard patches, swelling, abnormal growth of organs and tenderness 
can be felt. 
 In venpulli – hypopigmented patches present. 
 
 NAA: 
 Signs and symptoms in the tongue are noted here. Colour, salivary secretion, ulcers, 
coating, inflammation, taste changes, deviation and its nature are generally noted. 
 In venpulli in anaemic conditioned tongue may be pallor. 
 
NIRAM: 
 The colour of the skin is noted here. 
 In  venpulli –  the natural skin color become white. 
 
MOZHI: 
 Character of the speech is noted, mainly uraththa oli (high pitched), thazhndha oli (low 
pitched), or resembles the sound of any instrument. 
 In venpulli no changes in voice. 
 
VIZHI: 
 Character of the eye is noted. Colour, warm, burning sensation, irritation, visual 
perception are generally noted. 
 In venpulli no changes in vizhi. 
 
MALAM: 
 The stools are examined for quantity, hardening (malakattu), loose motion (bedhi), colour 
and smell. 
 In venpulli no changes. 
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MOOTHIRAM: 
a) NEERKURI (Urine examination) 
 Urine examination is good diagnostic method compare to naadi and other Envagai 
thervugal. Theraiyar mention it as. 
“அருந்துமாறிைதமும் அவிபைாதமதாய் 
அஃகல் அலர்தல் அகாலவூண் தவிர்ந்தழற் 
குற்றளவருந்தி உறங்கி கவகககற 
ஆடிக்கலசத் தாவிபய காது வபய் 
வதாருமுகூர்த்தக் ககலக்குட்படு நீரின் 
நிறக்குறி வநய்க்குறி நிருமித்தல் கடபன” 
                                                          noi nadal noi mudhal nadal thirattu, part-i (pg no-282) 
 
 The early morning urine sample is collected and sample should be examined within one 
and hour hours. 
 
SIRUNEERIN POTHU GUNAM: 
    “வந்த நீர்க்கரி எகட மணம் நுகை எஞ்சவலன 
     கறந்தியலுளகவ யகறகுது முகறபய” 
                          noi nadal noi mudhal nadal thirattu, part-i (pg no-282) 
 
                  The urine is examined for its Niram (colour), Eadai (Specific gravity), Nurai (Froth), 
Natram (Smell), Enjal (Deposits). 
      
 
NIRAM (COLOUR) 
NIRA THOGAI 
 “பீதம் வசம்கமகபங் கருகம வவண்கமவயன்று 
        பறாகதங்வகாழுகமகய வயாத்துகு நீபை” 
   noi nadal noi mudhal nadal thirattu, part-i (pg no-283) 
 
1. Yellow 
2. Red 
3. Green 
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4. Black 
5. White  
Urine may be any colour as mentioned above. 
 
EADAI (SPECIFIC GRAVITY) 
 Urine, not thick is considerably healthy. This is mentioned as 
“மிகத் தடிப்பும் மிகத் பதறலும் இன்வறனில் 
சுகத்கத தரும் வமய்ச் சுபாவ நீர் நன்பற” 
                     noi nadal noi mudhal nadal thirattu, part-i (pg no-294) 
  
NURAI (FROTH) 
 Urine may be frothy in nature, if it is reduced in vali, azhal and ayyam are said to be 
deranged. This is mentioned as 
 
நுகைபதய்த் வதாழுகு நீர் நுவலுரும் மும்மலம் 
ககைய இளகிடும் காலத் வதன்பன” 
                       noi nadal noi mudhal nadal thirattu, part-i (pg no-296) 
  
NAATRAM (SMELL) 
 Foul odour with pyuria is observed in patients with urinary lithiasis associated with 
urinary tract infection and ulcer. This is mentioned as 
   
  “வவய்ய துர்க்கந்தம் வசீுநீர் மூத்திைப் 
கபநாளமிவற்கறப் பற்று புண்குறிபய 
அம்வமாழியின் வறனினனிலபம முதலிய 
மும்மலச் சுதபம மூலவமன் றுணபை.” 
                    noi nadal noi mudhal nadal thirattu, part-i (pg no-294) 
 
ENJAL (DEPOSITS) 
 If urine excretion look like curd water white colour and sand like deposits in urine 
indicate stones in kidney. This is mentioned as 
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“நார்த்ததி நீகைபபால நகவயுற்றங் கிழியுமானால் 
மாைற்ப முற்றநீரி லடிமண்டிக் கிடந்த தானால் 
பாரிந்த வமழுகுமாங்காய் பற்றிய கல்லினாபல 
சரீுற்ற வசய்ககவயன்று வதறிவுறச் வசப்பலாபம” 
 noi nadal noi mudhal nadal thirattu, part-i (pg no-321) 
 
NEIKURI 
 The early morning urine of the patient is analyzed by dropping a drop of gingely oil on 
the surface of the urine sample. The accumulation, formations, changes, and dispersal under the 
sunlight without any external disturbances of the urine sample can be noted. 
The urine kept on the kidney tray in sun light, on non wind condition, should be 
examined by dropping a drop of gingili oil gently with rod. If oil spread like snake, it indicates 
vali neer; a ring indicates azhal neer and float like a pearl indicates iyya neer and sinks in urine 
indicates mukkutram. 
   
“அைவவன நீண்டினஃபக வாதம் 
ஆழி பபாற்பைவின் அஃபத பித்தம் 
முத்வதாத்து நிற்கின் வமாழிவவதன் கபபம” 
                       noi nadal noi mudhal nadal thirattu, part-i (pg no-298 - 299) 
 
 Vatha neer – The oil spreads like snake 
 Pitha neer – The oil spreads like ring 
 Kabha neer – The oil spreads like pearl 
 If the oil spreads gradually, it indicates good prognosis 
 If the oil spreads fast or gets mixed completely with urine or sinks in urine, it suggests 
bad prognosis. 
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MODERN ASPECT 
Dermatology is the branch of medicine dealing with both normal and 
abnormal skin and associated  structures such as hair, nails, and oral and genital 
mucous membranes. 
 
IMPORTANCE OF DERMATOLOGY 
 Skin diseases are very common, affecting up to a one third of the population at 
any one time.    
 Skin disease is often easily noticeable than other disease so this is a cause of 
great social concern to the patient. 
 Skin diseases have serious impacts on life. They can cause physical damage,  
embarrassment, and social and occupational restrictions. Chronic skin diseases 
may cause financial constraints with repeated sick leave. Some skin conditions 
can be life-threatening.   
 
SKIN ANATOMY 
The skin is the largest organ of the body, with a total area of about 20 square feet. 
The skin protects us from microbes and the elements, helps regulate body temperature 
and permits the sensations of touch, heat and cold. 
Skin has three layers: 
 The epidermis, the outer most layer of skin, provides a waterproof  barrier and 
creates our skin tone. 
 The dermis, beneath the epidermis, contains tough connective tissue, hair 
follicles, and sweat glands. 
 The deeper subcutaneous tissue (hypodermis) is made of fat and connective 
tissue. 
Epidermis develop from the ectoderm and dermis from the mesoderm. The 
general ectoderm of the early human embryo consists of single layer of cuboidal cells. 
By fifth week of intra-uterine life, this become double layered. The most superficial 
layer of flattened cells is called Periderm or epitrichium because the hair later grow 
from the deeper layer   
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3.2.1. Structure of the Skin 
About the fifth week of fetal development the epidermis and its appendages 
are developed from the ectoderm. End of second month of intra-uterine life - the 
derma consists of closely-packed, spindle-shaped mesenchymal cells.  
During third month of foetal life –three layers of cells are recognizable, the 
periderm, the intermediate and the basal layer which is close to the dermis. Fine 
reticulum fibres are demonstrable, which later increase in number and thickness, form 
the collagenous fibres.  
 The subcutaneous fat is apparent by the end of the third month of intra-uterine 
life, but it becomes abundant only during the later months of foetal life. The nail starts 
as an epidermal specialization on the dorsum of the tips of the digits. 
 During fourth month of foetal life - all the sweat glands and the subcutaneous 
fat are being to develop. During fifth month of foetal life the basal cells multiply 
rapidly.  
During the sixth month of the foetal life -The elastic fibres appear. Most of the 
sebaceous glands in the body develop in connection with hair 
 
 
EPIDERMIS 
The epidermis is the outer layer of skin. The top layer of epidermis composed 
of dead cells containing keratin, the horny protein that makes up hair and nail.The 
epidermis has no blood supply and is nourished almost exclusively by diffused 
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oxygen from the surrounding air. The thickness of the epidermis varies in different 
types of skin. It is the thinnest on the eyelids and thickest in palm and sole. 
It has 95% keratinocytes which produces a tough protein called keratin but 
also contains melanocytes, Langerhans cells, Merkel cells and inflammatory cells. 
Rete ridges are epidermal thickenings that extend downward between dermal papillae. 
Blood capillaries are found beneath the epidermis and are linked to an arteriole and 
a venule. 
The skin’s colour is created by special cells called melanocytes, which produce 
the pigment melanin. Melanocytes are located in the epidermis. 
 
Layers 
The epidermis is composed of  5 layers depending on the region of skin being 
considered. Those layers in descending order are,  
 
1. Stratum corneum / Horny layer 
 The most superficial layer of the epidermis from which dead skin sheds and is 
the thickest of epidermal layers having 15 – 30 layerrs of keratinized cells. 
 The Stratum corneum is also normally devoid of nuclelic and consists of 
eosinophilic layers of keratin.  
 Most of the barrier functions of the epidermis localize to this layer.  
2. Stratum lucidum 
 It is a clear or  translucent layer. 
 It is present only in palms and soles. 
 It is composed of flattened and hardened skin cells madeof keratin. 
3. Stratum granulosum ( Granular layer) 
 The stratum granulosm is one to four cellular layers thick consistitng of 
flattened rows of cells 
 This layer produces large amount of the protein keratin.  
 Keratin is extremely durable and water resistant.It is also the protein that 
forms the basic structure of hair and nails.  
4. Stratum spinosum / Spinous layer/ Pricky cell layer 
This layer is composed of several layers of polygonal prickle cells (or) 
squamous cells. The layers become flat as they are near the surface, so that their long 
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axis appears parallel to the skin surface. These cells possess intercellular bridges (or) 
Tonofilaments. 
Composed mainly of proliferating and non-proliferating keratinocytes, 
attached to the basement membrane by hemidesmosomes.  
Melanocytes are present, connected to numerous keratinocytes in this and 
other strata through dendrites.  
Merkel cells are also found in the stratum basale with large numbers in touch-
sensitive sites such as the fingertips and lips. They are closely associated with 
cutaneous nerves and seem to be involved in light touch sensation.[9] 
The epidermis is separated from the dermis, its underlying tissue, by a basement 
membrane. 
 
 
 
 
Melanocytes  
They are melanin producing neural crest derived  cells located in the bottom 
layer of the skin's epidermis, the middle layer of the eye , the inner ear, meninges, 
bones and heart. It is formed from tyrosine by oxidation metabolism and 
polymarization. 
They are spidery black cells that produce the brown to black pigment known 
as melanin.Melanin is the pigment primarily responsible for skin colour. Once 
synthesised, melanin is contained in a special organelle called a melanosome and 
moved along arm-like structures called dendrites, so as to reach the keratinocytes. 
 
 Layers of the skin 
5. Stratum Basal/germinal layer  
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DERMIS 
 
The dermis is a thick layer of skin between the epidermis and subcutaneous 
tissues, that primarily consists of dense irregular connective tissue and cushions the 
body from stress and strain. The dermis also varies in thickness depending on the 
location of the skin. The dermis is a tough layer of skin.  
The dermis is tightly connected to the epidermis through a basement 
membrane. Structural components of the dermis  
Collagen 
Elastic fibers 
Extrafibrillar matrix.  
The hair follicles, sweat glands, sebaceous glands, apocrine glands, lymphatic 
vessels and blood vessels are present in the dermis.  
The dermis is composed of three major types of cells   
Melanocytes 
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Fibroblasts 
Macrophages 
Adipocytes 
Dermis is divided into two layers, the superficial area adjacent to the epidermis called 
the papillary region and a deep thicker area known as the reticular dermis.    
 
Papillary dermis ( stratum papillarosum) 
The papillary dermis is the uppermost layer of the dermis.  It accounts for 1/5 
th of the dermis. It intertwines with the rete ridges of the epidermis and is composed 
of fine and loosely arranged collagen fibers.  
The papillary region is composed of loose areolar connective tissue. This is 
named for its finger like projections called papillae, that extend toward the epidermis 
and contain either terminal networks of blood capillaries or tactile Meissner's 
corpuscles 
The papillary layer provides the layer above it, the epidermis, with nutrients to 
produce skin cells called keratinocytes. It also helps regulate the temperature of our 
skin and thus the body as a whole.   
 
Reticular dermis (stratum reticularosum) 
The reticular dermis is the lower layer of the dermis, found under the 
papillary dermis, composed of dense irregular connective tissue featuring densely 
packed collagen fibers.  
The reticular layer serves to strengthen the skin and also provides our skin 
with elasticity. 
The reticular region is usually much thicker than the overlying papillary 
dermis. It receives its name from the dense concentration of collagenous, elastic, 
and reticular fibers that weave throughout it.  
 The reticular layer also contains hair follicles, sweat glands, and sebaceous 
glands.   
The sweat gland can either be apocrine, such as those found in the armpits and 
the groin area, or the eccrine glands, which are found all over the body. The former 
help contribute to body odor and the latter help regulate our body temperature through 
the process of evaporation.  
35 
 
The sebaceous glands found in the dermis secrete a substance 
called sebum that helps to lubricate and protect our skin from drying out. 
 
HAIR 
The hair grows from the bottom of the follicle. It has, therefore, an 
intracutaneous portion present in the hair follicle and the shaft. The hair follicle 
consists of epithelial and connective tissue components. Hair is composed primarily 
of keratin. The dead keratinocytes fuse together to form the hair.  
 
ARRECTORES PILORUM 
These are small bundles of smooth muscle attached to each hair follicle that 
contracts in response to cold, fright and other emotions. When the muscle contracts, 
the hair becomes more erect, the follicle is dragged upwards so as to become 
prominent on the surface of the skin producing what is known as ‘goose skin’.   
 
NAILS 
The nails are thickening of the deeper part of the stratum corneum that 
develops as specially modified portion of the skin called nail bed. The nails is 
composed of clear horny cells, resembling stratum lucidum but are much more 
keratinized.    
The dermis also contains: 
 Nerve endings that transmit various stimuli such as pain, itch, pressure, and 
temperature. Specialized Nerve Cells 
 Pacinian corpuscles –pressure receptor 
 Meissner corpuscles– touch receptor  
 Ruffini corpuscles– hot receptor 
 End bulbs of Krause –cold receptor  
 Free nerve ending– pain receptor 
 Lymphatic vessels that transport immune system cells, the cells that help 
destroy infectious organisms that may have found their way into our body via 
a scratch on the skin. 
 Collagen, a protein that helps strengthen our skin, and elastin, a protein that 
helps keep our skin flexible. 
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 The dermis is well supplied with blood vessels, both arterioles and capilleries 
that originate from arteries and veins in the subcutaneous layer. Blood vessels 
within the dermis supply nutrients to the stratum basale as well as to the 
cellular structures of the dermis such as glands and hair follicles. Those blood 
vessels provide nourishment and waste removal for both dermal and epidermal 
cells. 
 HYPODERMIS / SUBCUTANEA 
 Beneath the dermis is the deepest layer of our skin.  
 It contains many collagen cells as well as fat.  Fat, in particular, helps insulate 
our body from the cold and act as a cushion for our internal structures. 
 
PHYSIOLOGY   
FUNCTIONS OF THE SKIN:  
1. PROTECTIVE FUNCTION 
 It protects underlying tissues and organs from chemicals, microbes and shock 
impacts. The cornified layer of the epidermis possess properties of physical 
toughness, strength, flexibility, elasticity and also retards proliferation of 
microorganism and their penetration. The skin protects the body from from ultra 
violet damage from the sun by producing melanin. 
 
2. THERMOREGULATION  
The skin contains several types of receptors which are involved in 
thermoregulation. Skin regulates body temperature by constricting blood vessels and 
driving blood inward in cold temperatures to preserve body heat and produce sweat in 
warm temperatures to cool the body by water evaporation.  
 
3. SENSE ORGAN  
  Sensation is a very important function of the skin. Skin preserves a number of 
sensations like touch, pressure, warmth, cold and pain  
 
4. STORAGE FUNCTION 
The skin acts as two way barrier to prevent the inward or outward passage of 
water and electrolyte. The dermis and subcutaneous fatty tissue acts as storage organ 
of energy and others. It synthesize and stores vitamin D.  
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5. ABSORPTION  
The skin surface also performs absorptive function and is the basis of topical 
therapy in dermatology. The skin is capable of absorbing fat soluble nutrients such as 
vitamins A, D, E and K. 
 
6. EXCRETION  
Some of the toxins may be excreted through the skin.  
 
7. IMMUNE SURVEILLANCE  
This immunological function is performed by langerhans’ cells, dendritic cell, 
and keratinocytes. Thus the skin forms the front line defense of the body against 
invasion by foreign agents.  
 
8. MECHANICAL FUNCTION  
The mechanical properties of the skin depend mainly on the dermis, although, 
the epidermis and subcutaneous fats also plays some role.  
 
9.  COSMETIC FUNCTION  
Colour of the skin, hair and nail are important for their decorative value. Hair 
does not perform a vital physiological function but it does provide a sexually 
attractive ornament.  
 
Melanin Formation 
 Melanin synthesis is initially catalysed by a copper containing enzyme known 
as tyrosinase.    The broad of melanin synthesis from the oxidation of phenylalanine 
or tyrosine are as follows.   
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Melanin produced in the melanocytes is donated via their dendrites to 
neighbouring keratinocytes. Melanin formation in both human and amphibian skin is 
augmented by the hormone known as intermedin or melanocyte – stimulating 
hormone (MSH) secreted by the pars intermedia of the pituitary gland.  
Adrenocortico tropic hormone (ACTH) secreted by Anterior Pituitary has 
melanocyte – stimulating activity similar to MSH although to a much lower degree. 
 MSH causes the serum copper to rise and this is accompanied by inner case in 
the melanin formation.  
Diminished formation of melanin is seen in albinism and leucoderma. In 
melanotic sarcoma, melanin may be found in the urine.  
  
Melanin Formation 
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VITILIGO  
White skin is the literal meaning of leucoderma, derma being derived from the 
Greek words, leucas and dermis. Leucas means white and dermis means skin.  
Vitiligo is a non contagious acquired pigmentation disorder characterized by 
sharply defined white patches of variable shape and dimensions, increasing in size 
and number with time.   
The disorder affects all races and both sexes equally, however, it is more 
noticeable in people with dark skin 
 
DEFINITION 
Vitiligo is defined as acquired idiopathic , circumscribed, progressive 
hypopigmentation of skin and hair. A type of leucoderma often familial characterized 
microscopically by an absence of melanocytes.  
This disease is characterized by the presence of white macules or patches on 
the skin caused by the loss of functioning epidermal melanocytes Vitiligo can also 
affect the mucous membranes  and the eye.  
It can be examined by naked eye and can furnish a lot of information about the 
person and the disease.  
 
EPIDEMIOLOGY  
Vitiligo is an hypopigmentation disorder that affects approximately 1-2 % of 
the population worldwide. 
 In India 0.25-2.5% were affected. 30% hereditary condition.  
Stable type of vitiligo was common which accounted for 65.21%. Lower lip 
was involved in 75% of mucosal vitiligo.  
Lower limbs were the most common site of onset of vitiligo. Family history 
exists in 6.25%-38% of patients with vitiligo 
 
HISTOPATHOLOGIC CHANGES IN VITILIGO  
 Absence of melanocytes 
 Negative silver stain for melanin  
 Negative dopa reaction  
 Lymphocytic inflammation may be seen  
 Melanophages may be seen.  
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 In the affected area the basal cells and the keratinzing cells of the other layers of 
epidermis do not contain melanin pigment granules in them.   
 At the border of the patches of vitiligo the melanocytes often appear large and 
posses long dendritic process filled with melanin granules.  
 Electron microscopic studies confirm the absence of melanocytes in areas of long 
standing vitiligo.  
 There are collections of mononuclear cells at dermo epidermal junction at the 
border between vitilliginous and normal skin. These cells are predominately small 
lymphocytes. In the long standing cases where the skin has become thick and 
scaly, varying amount of keratosis is seen. 
 
PATHOPHYSIOLOGY:  
                                        
 
 
 
 
 
 
 
 
Vitiligo is a cutaneous pigmentary disorder caused by selective destruction of 
melanocytes and is characterized by progressive, patchy loss of pigmentation from 
skin.Vitiligo has been proposed to be a multifactorial disease with genetic 
susceptibility and environmental factors both thought to play a role.  
The TYR gene encodes the protein tyrosinase, which is not a component of the 
immune system, but is an enzyme of the melanocyte that 
catalyzes melanin biosynthesis, and a major autoantigen in generalized vitiligo. 
  Although several theories have been proposed about the pathogenesis of 
vitiligo, there are a few major hypothesis for the pathogenesis of vitiligo which 
include the genetic, neural, autoimmune, Oxidant-antioxidant mechanisms and 
melanocytorrhagy theories.   
 
Pathogenesis of Vitiligo 
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Autoimmune and cytotoxic hypotheses 
Aberration of immune surveillance results in melanocyte dysfunction or 
destruction.   Autoimmune diseases such as thyroid diseases  and diabetes mellitus  
are often associated with vitiligo. These diseases cause defects in the immune system, 
which can cause destruction of melanocytes and the loss of pigmentation . The 
autoimmune theory proposes alteration in humoral and cellular immunity in the 
destruction of melanocytes of vitiligo. 
 
 In addition, antibodies against melanocytes were found in serum of patient, 
and these can engage the apoptosis of melanocytes when they are present . T cells 
were also found in perilesional vitiligo plaque biopsies and they are enriched with 
cytotoxicity against melanocyte antigens. Destruction of melanocytes may be directly 
mediated by autoreactive CD8+ T cells. Activated CD8+ T cells have been 
demonstrated in perilesional vitiligo skin. 
 
Vitiligo is sometimes associated with autoimmune and inflammatory 
diseases such as Hashimoto's thyroiditis, scleroderma, rheumatoid arthritis, type 1 
diabetes mellitus, psoriasis, Addison's disease, pernicious anemia, alopecia 
areata, systemic lupus erythematosus, and celiac disease. 
 
Neural hypothesis 
A neurochemical mediator destroys melanocytes or inhibits melanin 
production.   The neural hypothesis is based on the contact of the melanocytes with 
nerve endings in depigmented skin . Neuropeptides and nerve growth factors such as 
tumor necrosis factor-α, intercellular adhesion molecule-1 and interferon-γ were 
found in perilesional skin, which suggest that nerves can have a role in destruction of 
melanocytes . The toxic hypothesis suggests that the mechanism of natural protection 
of melanocytes is defective. The melanocytes are unable to eliminate toxic molecules, 
and these are accumulated in the cells 
 
Oxidant-antioxidant mechanisms 
An intermediate or metabolic product of melanin synthesis causes melanocyte 
destruction. Studies suggest that accumulation of free radicals toxic to melanocytes 
leads to their destruction. Because patients with Vitiligo exhibit a characteristic 
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yellow/green or bluish fluorescence in clinically affected skin, this led to the 
discovery that the fluorescence is due to accumulation of 2 different oxidized 
pteridines. The overproduction of pteridines led to the discovery of a metabolic defect 
in tetrahydrobiopterin homeostasis in patients with Vitiligo, which results in the 
accumulation of melanocytotoxic hydrogen peroxide. 
 
Melanocytorrhagy hypothesis 
It emphasizes that depigmentation is because of chronic detachment of 
melanocytes. Trauma or repeated friction can contribute toward the detatchment of 
melanocytes over time. Melanocytes in unstable vitiligo have been found to lose the 
ability to adhere to key surrounding structures. Tenascin, an extracellular matrix 
molecule that inhibits adhesion of melanocytes to fibronectin, has been detected in the 
basal membrane in the papillary dermis and can contribute toward chronic 
detatchment and epidermal loss of melanocytes.   
 
Genetics of vitiligo 
The inheritance of vitiligo may involve genes associated with the biosynthesis 
of melanin, a response to oxidative stress, and regulation of autoimmunity.   Human 
leukocyte antigens (HLAs) may be associated, but not in a consistent manner.  
 
For example, HLA-DR4 is increased in blacks, HLA-B13 is increased in 
Moroccan Jews, and HLA-B35 is increased in Yemenite Jews. An association with 
HLAB13 is described in the presence of antithyroid antibodies.  Only one gene, 
SMOC2, is in the region of association, within which SNP rs13208776 attained 
genome-wide significance for association with other autoimmune diseases and vitiligo  
Other Common factors are,  
 Nutritional - defects in copper, proteins and vitamins in diet, digestive upsets 
like amoebiasis, helminthics, chronic diarrhoea, dysentery etc.,  
 Endocrines – Association with thyrotoxicosis and diabetes.  
 Trophoneurosis and autonomic imbalance – emotional stress and strain.  
 Infections and toxic products, Enteric fever ill health, focal sepsis.  
 Drugs and chemicals  
 Triggers also include inflammatory skin conditions, burns, intralesional steroid 
injections and abrasions. 
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Clinical features 
White patches on the skin are the main sign of vitiligo. These patches are more 
common in areas where the skin is exposed to the sun.  
 
The patches may be on the hands, feet, arms, face, and lips. Other common 
areas for white patches are: 
The armpits and groin (where the leg meets the body), around the mouth, eyes,  
nostrils,  navel, genitals,  rectal areas, Loss of colour in the tissues that line the inside 
of your mouth and nose (mucous membranes), Loss of or change in colour of the 
inner layer of the eyeball (retina) 
People with vitiligo  often have hair that turns gray early. Those with dark skin 
may notice a loss of colour inside their mouths.  
Initially, the vitiligo starts as a simple spot, a little paler than the rest of the 
skin. But gradually, as time passes, this spot will become much paler until it becomes 
white. 
The shape of these patches are completely irregular, and, at times, the edges 
can become a little inflamed with a slight red tone, sometimes resulting in itchiness. 
 Other than the appearance of the spots and occasional itchiness, vitiligo does 
not cause any discomfort, irritation, soreness or dryness in the skin. 
Predicting whether vitiligo will spread, and by how much, is particularly 
difficult. The spread of white patches might occur in a matter of weeks for some, and 
for others, they might stabilize, not growing for months or even years. 
If the first symptoms of the white patches are symmetrical (non-segmental 
vitiligo), the development is much slower than if the patches are in only one area of 
the body (segmental vitiligo). 
Depending on the type of vitiligo, the discolored patches may cover: 
 
Many parts of the body 
With this most common type, called generalized vitiligo, the discolored 
patches often progress similarly on corresponding body parts (symmetrically). 
 
Only one side or part of  the body 
This type, called segmental vitiligo, tends to occur at a younger age, progress 
for a year or two, then stop. 
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One or only a few areas of the body  
This type is called localized (focal) vitiligo. Sometimes the patches stop 
forming without treatment. In most cases, pigment loss spreads and eventually 
involves most of your skin. Rarely, the skin gets its color back. 
 
Types of vitiligo 
Scientists separate vitiligo into two types 
 Non-segmental vitiligo 
 Segmental vitiligo. 
 
Non-segmental vitiligo 
Non-segmental vitiligo is the most common type of vitiligo and occurs in up 
to 90% of people who have the disorder. In non-segmental vitiligo, the patches often 
appear equally on both sides of the body, with some measure of symmetry. 
 
 New patches also appear over time and can be generalized over large portions 
of the body or localized to a particular area.  
 
NSV can come about at any age .The symmetrical patches most commonly 
appear on skin that is exposed daily to the sun, such as the face, neck and hands, but 
can also appear in other areas: 
 Backs of the hands 
 Arms 
 Eyes 
 Knees 
 Elbows 
 Feet 
 Mouth. 
 
Non-segmental vitiligo is further broken down into sub-categories: 
Generalized vitiligo 
  No specific area or size of patches, this is the most common type 
Acrofacial vitiligo 
 Mostly on the fingers or toes 
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Mucosal vitiligo 
Depigmentation generally appears around the mucous membranes and lips 
Universal vitiligo 
Depigmentation covers most of the body, this is very rare 
Focal vitiligo 
  One or  few, scattered white patches in a discrete area. Most often occurs in 
young children. 
Segmental vitiligo 
Segmental vitiligo has a different form; this condition spreads more rapidly 
but is considered more constant and stable than non-segmental. It is much less 
common and affects only about 10% of people with vitiligo. 
 
Segmental vitiligo is more noticeable in early age groups, affecting about 30% 
of children diagnosed with vitiligo. 
 
It is non-symmetrical and usually tends to affect areas of skin attached to 
nerves arising in the dorsal roots of the spine. It is more stable, less erratic and 
responds well to topical treatments. 
 
Complications 
People with vitiligo may be at increased risk of: 
 Social or psychological distress 
 Sunburn and skin cancer 
 Eye problems, such as inflammation of the iris (iritis) 
 Hearing loss 
 
PATIENT EVALUATION 
Assessment of severity — The evaluation of the patient with vitiligo involves a 
detailed history and a complete skin examination to assess disease severity and 
individual prognostic factors. Factors that may influence the approach to treatment 
include: 
●Age at onset of lesions 
●Type of vitiligo (segmental, nonsegmental) 
●Mucosal involvement, Koebner phenomenon 
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●Rate of progression or spread of lesions 
●Previous episodes of repigmentation 
●Type and response to previous treatments 
●Family history of vitiligo and/or autoimmune diseases 
●Presence of concomitant diseases 
●Current medications and supplements 
●Occupation, exposure to chemicals 
●Effects of disease on the quality of life 
 
A full-body skin examination should be performed to assess the extent of the 
disease, with particular attention to sites of vitiligo predilection, such as the lips and 
perioral area, periocular areas, dorsal surface of the hands, fingers, flexor surface of 
the wrists, elbows, axillae, nipples, umbilicus, sacrum, groin, inguinal / 
anogenital regions, and knees.  
 
The percentage of the body area involved can be estimated by the so-called 1 
percent rule or "palm method." In both children and adults, the palm of the hand, 
including the fingers, is approximately 1 percent of the total body surface area 
(TBSA), while the palm excluding the fingers is approximately 0.5 percent of the 
TBSA. An alternative method is the "rule of nines": 
●Each leg represents 18 percent of the TBSA. 
●Each arm represents 9 percent of the TBSA. 
●The anterior and posterior trunk each represent 18 percent of the TBSA. 
●The head represents 9 percent of the TBSA. 
 
Goals of treatment  
The goals of treatment for vitiligo should be set with the individual patient or 
parents in the case of children, based upon the patient's age and skin type, the extent, 
location, and degree of disease activity, and the impact of the disease on the patient's 
quality of life. An open discussion with the patient about the limitations of treatment 
may be helpful to create realistic expectations. 
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Psychosocial aspects  
The patient's psychologic profile and ability to cope with a lifelong disease 
should be carefully evaluated at the time of treatment planning. Psychologic support 
should be offered to patients if needed 
The main symptom of vitiligo is the appearance of lesions, with an often 
distressing sense of disfigurement and associated stigma. 
 Social isolation, reduced sense of worth, adverse effects on education, 
occupation, and personal relationships and depressive illness can be consequences 
Inferiority complex immediately following the start of disease, the patient 
thinks himself inferior to those with whom he was at par or excelled for so long.  
 When the patient feels his disease is incurable he becomes gradually 
depressed. 
 
Diagnosis:  
1. The distribution, the age of onset and the hyper pigmented border will suggest 
the diagnosis.  
2. Vitiligo areas are milky white while other lack this milky white colouration.  
3. It is usually apparent. In doubtful and early case, Wood’s lamp is great help in 
diagnosis.  
4. Careful examination of the texture of the unpigmented skin should exclue 
lichen sclerosus and scleroderma.  
5. Post-inflammatory leucoderma, which is frequent in the darker races, shows an 
irregular mottling of hyper pigmented and hypopigmented blotches.  
6. Stationary patches are well-defined and have hyperpigmented borders.  
7. Sensations are normal, so is texture unless the patches have been irritated with 
treatment.  
8. Absence of scaling, crusting and itching help to eliminate seborrhoeids and 
pityriasis versicolor.  
9. These areas often fluorescence a golden yellow when examined under a 
Wood’s lamp. The hypomelanotic macules in leprosy are anaesthetic.  
10. Examination of the skin in long wave UVR helps distinguish whether there is 
total depigmenation (as in Vitiligo) or not. It may also detect areas of depigmenation 
not easily seen in ordinary daylight, as well as detecting a lemon-yellow fluorescence 
seen in some cases of pityriasis versicolor.  
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Differential Diagnoses 
 
Pityriasis alba 
 It appears as white patches on the upper arms and sometimes the thighs. Close 
examination shows an indistinct border and fine surface scale. 
Tinea versicolor 
 It is casused by yeast. It affects the chest and back. Patches have a fine scale 
on the surface. The colour of the patches varies from pale to orange brown.  
Halo nevi 
It develop a white border. One or several of these nevi may be present on the back of 
children. 
Leprosy 
  One or several paler macules on trunk or limbs that are hypoaesthetic.  
White macules of affecting tuberous sclerosis 
Uncomming development of anomaly of CNS, connective tissue and skin; 
several “maple leaf” shaped hypopigmented macules.  
Post inflammatory hypopigmentation  
After inflammatory skin disease (after eczema or trauma to the skin; irregular 
in shape and in depth of pallor).  
Chemical toxicity  
May look very much like vitiligo; seen in workers in rubber industry exposed 
to parateriary benzyltoluence.  
Outlook (Prognosis) 
The course of vitiligo varies and is unpredictable. Some areas may regain 
normal pigment , but other new areas of pigment loss may appear. Skin that is 
repigmented may be slightly lighter or darker than the surrounding skin. Pigment loss 
may get worse over time. 
 
Treatment 
 Vitiligo is difficult to treat. Early treatment options include the following: 
 Phototherapy, a medical procedure in which your skin is carefully exposed to 
ultraviolet light. Phototherapy may be given alone, or after you take a drug 
that makes your skin sensitive to light. 
 Certain lasers may help the skin repigment. 
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 Medicines applied to the skin, such as corticosteroid creams or ointments, 
immunosuppressant creams or ointments such as pimecrolimus (Elidel) and 
tacrolimus (Protopic), or topical drugs such as methoxsalen (Oxsoralen) may 
also help. 
 Skin may be moved (grafted) from normally pigmented areas and placed onto 
areas where there is pigment loss. 
 Several cover-up makeups or skin dyes can mask vitiligo.  
 In extreme cases when most of the body is affected, the remaining skin that 
still has pigment may be depigmented. This is a permanent change that is used 
as a last option. 
 It is important to remember that skin without pigment is at greater risk for sun 
damage. Be sure to apply a broad-spectrum (UVA and UVB), high-SPF 
sunscreen or sunblock.  
 Sunscreen can also be helpful for making the condition less noticeable, 
because unaffected skin may not darken in the sun.  
 Use other safeguards against sun exposure, such as wearing a hat with a broad 
rim and long sleeve shirt and pants. 
 Surgical therapies — Surgical therapies have been used for vitiligo for the past 
25 years and remain viable options for patients with localized depigmented 
areas that have been unresponsive to medical intervention. 
 
They include: 
 Autologous suction blister grafts  
 Minigrafts or punch grafts  
 Split-thickness grafts  
 Autologous melanocyte cultures 
 Cultured epidermal suspensions  
 Autologous noncultured epidermal cell suspension  
 Hair follicle transplantation  
 
DIET AND RESTRICTIONS 
 Occupation  
 Cosmetic things  
 Diet  
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 During bathing – the powder of Bengal gram and green gram or any other 
herbal products can be used.  
 Vinegar, cooking soda, food enriched with alcohol must be avoided. These 
items may promote bleaching of skin pigment.  
 Using soaps and detergents also promote bleaching of skin.  
 Copper and zinc content vegetable such as cooked green gram or Bengal gram 
at least one time a day.  
 Highly nutritious food like spinach, pomegranate, cheese, butter, milk, 
almond, germinating grams and foods rich in tyrosinase to be added.  
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DRUG REVIEW 
                             INTERNAL MEDICINE:  RASA CHENDHURAM 
 
INGREDIENTS: 
 Rasam (Hydragyram)          
 Gandhagam (Sulphur)    
Aridharam  (Arsenic trisulphide)      
            Egg shell       
RASAM  (HYDRAGYRUM) 
                     Rasam comes under the classification of pancha sootham. It is one of the 
important siddha  raw drugs . 
 
 
                     
 
 
 
 
 
 
                  
இரசத்தின் ப ொதுக்குணம் 
      விழிந ொய் கிரந்தி குன்மம் பமய்ச்சூலை புண்குட் 
      டழிகொைில் விந்துவினொல் அத்லத – வழியொய்  
      புரியு விதி யொது புரியிநனொ பயல்ைொம் 
      இரியுவிதி யொது மில்லை 
 
Uses  : It cures venereal diseases  , skin diseases , eight types of ulcers. 
Taste  : six tastes present, sweet is dominant. 
Potency : hot and cool 
Action  : alterative, antiseptic, purgative, diuretic, tonic 
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GENERAL  PROPERTIES :  
Atomic number : 80 
Phase   : liquid 
Melting point  : 234.3210 
Heat of fusion  : 2.29 kj /mol 
Heat of vaporization : 59.11 kj / mol 
 
GANDHAGAM   (SULPHUR) 
Gandhagam comes under the division of paadanangal. It is one of the most 
useful raw drug in siddha. 
 
                   
            
 
 
 
 
 
ப ல்ைிக்கொய்க் கந்தகத்தின் ப ொதுகுணம் 
                                           (GOOSEBERRY SULPHUR)                                                
         “ப ல்ைிக்கொய்க் கந்திக்கு  ீள் திபனண் குட்டமந்தம் 
         வல்லை கவிலசகுன்ம வொயுகண்நணொய் – ப ொல்ைொ 
         விடக்கடிவன் நமகந ொய் வறீுசுரம் ந தி 
         திடக்கிரசு ணகீ ம்ந ொனந் நதர்.” 
 
 Uses: It cures eighteen   types of skin diseases, leprosy, veneral diseases, ulcer, etc,.   
 Taste:   kaippu, thuvarppu 
Action :  astringent,  laxative, alterative, insecticide 
General  properties :  
Atomic number : 16 
Phase   : solid 
Melting point  : 388.36 k 
Heat of fusion  : 1.727  kj /mol 
Heat of  vaporization : 45 kj / mol 
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THALAGAM  ( YELLOW ARSENIC TRISULPHIDE) 
Thalagam is come under the division of padanangal. It is one of the important 
raw drug in siddha system. 
 
                                                   
                        
 
 
 
 
 
 
தொளகம் ப ொதுக்குணம் 
      “தொளகத்தின் ந ருலரக்கத் தொலுகவுள் ந ொய்குஷ்டம் 
       ீளக் குளிர்கொய்ச்சல்  ீடுக ம் –  ொளகங்பகொள் 
      துஷ்டப்  ரங்கிப்புண் சூழழுகண் மண்லடந ொய் 
      கிட்டப்  டு மொ கிளத்து.”  
  
uses:  it is effective in treatment of  skin diseases, urinary tract infections, incurable 
ulcers, etc.                      
Action :  antipyretic , expectorant , emetic , convalescent , tonic. 
 
EXTERNAL MEDICINE:  PALAGARAI  KUZHAMBU 
 
INGREDIENTS: 
Palagarai (Marine shell)  
Lemon juice 
Gingelly oil 
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PALAGARAI  (CYPREA MONETA) 
Palagarai is considered as one of the five wealth of the sea. The white marine 
shell is considered as superior for medicinal purposes 
 
 
                 
 
 
 
 
 
PALAGARAI 
 ைகலை ப ொதுக்குணம் 
 
மந்தந்தொ கங்கிரகணி மொவிடச் சுரங்கண்நணொய் 
பதொந்தம்  ரி ொமச் சூலைகய – மிந்த  
வுைகலைலயக் கொபைொடிலவ நயொடு  லரத்த   
 ைகலைலய கொணினியம்  ொர். 
 
 
Uses: it cures skin diseases, jaundice, liver enlargement, spleen enlargement, eye 
diseases etc.  
suvai:  kaippu 
action: rubifacient, Stimulant, Expectorant, Demulcent. 
 
LEMON 
Botanical name : citrus limon 
Family : rutaceae 
 
                                         எலுமிச்லச ப ொதுக்குணம் 
 
தபீதலு மிச்சங்கொய் நடர்முத்நதொ டத்லதயுமுள் 
வொதக  சூலைலயயும் மொபகொடிய – சொதிபயனுஞ் 
சர்த்திகுன் மத்லதயுமுள் தங்கமருந் திட்டலதயும் 
 ித்தபவப்ல  யுந்தணிக்கும் ந சு.   
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suvai:  pulippu 
action: anti bacterial , anti fungal , antimicrobial, anti oxidant 
        
                                     
GINGELLY OIL 
 Botanical name:  Sesamamum indicum  
Family: meliaceae  
Parts used: seed 
 ல்பைண்பணயின் ப ொதுக்குணம் 
“புத்தி யனக்குளிர்ச்சி பூரிப்பு பமய்ப்புளகஞ் 
சத்துவங் கந்தி தனியிளலம – பமத்தவுண்டொங் 
கண்நணொய் பசவிந ொய் க ொைவழல் கொசந ொய் 
புண்நணொய் ந ொ பமண்பணய்யொற் ந ொற்று. “ 
Uses: oil used for cooling effect , external application for wounds and scabies. 
 Suvai : inippu 
 
 
                
 
 
 
 
 
 
Actions : Antifungal, Anticancer, Anti Aging, Anti coagulant, Anti Inflammatory 
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MATERIALS   AND  METHODS: 
 
SELECTION OF THE TRIAL MEDICINES: 
I have selected the trial drug “ Rasa  Chendhuram” (Int) for this study 
from Classical Siddha literature Pulipanni Vaithiyam -500
 
and “palagarai 
kuzhambu” (Ext)  from    Gunapadam-thaadhu seevavaguppu.  
 
SOURCE OF RAW  DRUGS: 
The required raw drugs are produced from as well reputed indigenous drug 
shop. The raw drugs will be authenticated by the concerned pharmacognosist, 
Government siddha medical college, ,arumbakkam, Chennai.  As i have registered my 
trial in clinical registry of India (CTRI). My CTRI no is (CTRI/2017/07/008969) . 
  
STANDARD OPERATING PROCEDURE: 
 
MEDICINE – 1 
RASA CHENDHURAM 
 INGREDIENTS: 
Rasam (Hydragyram)   - 35 gm 
Gandhagam (Sulphur)  - 35 gm 
Aridharam (Arsenic trisulphide) - 35 gm  
Egg shell    - Q.S 
 
METHOD OF PURIFICATION: 
PURIFICATION OF RASAM (MERCURY): 
Materials used : 
          Mercury , brick powder , turmeric powder , acalypha indica leaf juice. 
Equipments used: 
        Stove, mudplate. 
  
57 
 
Procedure: 
                                           
 
Mercury purification 
Mercury was tritured with brick powder and turmeric powder and washed with 
water. Then the mercury was boiled with acalypha juice for about 30  minutes . 
 
PURIFICATION OF GANDHAGAM (SULPHUR): 
Materials used : 
        Gandhagam  , milk 
 Equipments used: 
        Iron spoon, mud pot , stove , tissue paper. 
Procedure : 
 
        Trituration                   Mercury after purification 
Melting sulphur                         Sulphur poured into milk 
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  Gandhagam is placed in an iron spoon , the spoon is heated till the gandhagam 
melts. Then it is poured in milk. This is repeated for  2 times . After that gandhagam is 
taken out and washed with cool water and allowed it to dry. 
 
 PURIFICATION   OF ARSENIC TRISULPHIDIUM  (THALAGAM) : 
Materials used :  
 Thaalagam , limestone , small cloth 
Equipments used: 
Stove , mud pot , small cloth . 
Procedure : 
  
 
 
 
 
 
 
 
Thalagam is placed in small cloth and tied with a small rope. Then it was buried 
in limestone .  water was poured till the limestone immersed and it is heated  till water 
evaporated completely . the thalagam is taken out and washed in cool water and allowed 
it dry. 
  
                                                Sulphur after purification 
     Thalagam buried into limestone                  Thalagam after purification 
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METHOD OF PREPARATION: 
 
 
 
 
 
 
 
 
 
(Rasa chendhuram) 
 The above   mentioned purified raw drugs is to be added in the stone mortar and 
made as a fine powder.  Then the fine powder is to be fried well. Next the egg shell is 
powdered. Place the half the quantity of powdered egg shell in a mud plate as a layer. 
Then spread the powdered raw drug as a second layer then put the remaining quantity 
of egg shell spreaded on it, then it is heated with kukkuda pudam (10 cow dung cakes) 
to make as  a chendhuram. Then the end product is preserved in  an air tight container.    
DOSAGE  : 65 mg                                                          
ADJUVANT  : Palm jaggery. 
INDICATION : Parangisogai, Kiranthi, Kuttarogam, Thaadhunattam,  
Lingaputtru, Vippurudhi. 
  
Heating             Trituration   
 Final product 
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MEDICINE – 2 
EXTERNAL MEDICINE 
PALAGARAI  KUZHAMBU  
INGREDIENTS: 
 Palagarai (Marine shell) 
 Pazhacharu (Citrus limon) 
 Gingelly oil 
 
METHOD  OF  PREPARATION: 
Palagarai is powdered and kept in mud pot. Lemon juice is added to it, kept for 
6 days and allowed to dried.  The dried palagarai  is mixed well with gingelly oil and 
applied over the skin. 
INDICATIONS:  Kuttam, Kurainoi, pungal. 
 
STANDARDIZATION PARAMETERS : 
Traditional way of testing Chendhuram : 
1. Colour: 
Red in colour without any shiny appearance 
 
2. Taste and odour: 
Tasteless and odourless 
 
3. Luster 
Did not regain luster on heating again at same temperature 
 
4. Floating on water 
Sample floats on water. Did not immediately immersed in water 
 
5. Finger furrows test. 
Impinged in the papillary ridges when the sample rubbed in 
between Index   finger and thumb 
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PHYSICO- CHEMICAL ANALYSIS 
Determination of pH 
1% solution of Rasa Chendhuram was prepared in distilled water and pH was 
determined by using pH meter Systronics digital pH meter. 
 
Determination of moisture content 
 Moisture content was determined by LOD (Loss on Drying) method. 3gm 
VPM was taken and kept in oven at  105
0
c till  a constant weight was obtained. 
Amount of moisture present in the sample was calculated as referred to the air dried 
drug. 
 
Total Ash 
 A weighed amount of the powder was taken in a silica crucible previously 
ignited, cooled and weighed. It was incinerated using incinerator by gradually 
increasing the heat not exceeding dull red heat (450°C) until free from carbon, cooled 
and weighed. The percentage of ash was calculated with reference to air-dried drug. 
The procedure was repeated to get constant weight.  
 
Water soluble ash 
The total ash was boiled with 25 ml water and filtered through ash less filter 
paper (Whatmann 4.1). It was followed by washing with hot water. The filter paper 
was dried and ignited in a silica crucible, cooled and the water insoluble ash was 
weighed. The water-soluble ash was calculated by subtracting the water insoluble ash 
from the total ash. 
 
Acid insoluble ash 
The total ash obtained was boiled for 5 minutes with 25 ml of dilute hydrochloric 
acid (10% w/v) and filter through ash less filter paper (Whatmann No.1). The filter 
paper was ignited in a silica crucible, cooled and weighed. 
 
Determination of Alcohol Soluble Extractive 
The air dried drug was finely grounded, added with 100 ml of ethanol of 
specified strength in a closed flask for twenty-four hours, shaken frequently during 
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the course of six hours and allowed to stand for eighteen hours. Then the mixture was 
filtered rapidly taking precautions against loss of solvent, 25 ml of the filtrate was 
evaporated to dryness in a tarred flat bottomed shallow dish, and dried at 105º to 
constant weight. The percentage of alcohol-soluble extractive with reference to the 
air-dried drug was estimated. 
 
The obtained RASA CHENDHURAM  was given for instrumental analysis at cri 
arumbakkam  Chennai 
 
HEAVY METAL ANALYSIS 
Heavy metal Procedure  observation 
Mercury  1. Add 5ml of hydrochloric acid  to little 
substance, precipitate appears 
2.  Then  boil the precipitate with water. It 
does not dissolves add sodium hydroxide 
solution .heat it and fillter 
No black precipitaion 
appears 
Lead  1.add 2ml of potassium chormate to salt 
solution.  
No yellow precipitate 
appears 
Arsenic  To 10 drops of solution. Add 6ml NH3  until 
neutral.make the solution acidic b adding one or 
more drops of 6 M HCL. Add 1 ml of 
thioacetamide and stir well. Heat the test tube in 
the boiling water bath for 5 minutes  
No red orange precipitate  
Or 
No Yellow or brown 
precipitates appears 
Cadmium  add 2ml of solution, add 1 ml NaOH, add  1ml 
of distal water and add  1 ml of Hcl  
No Yellow  precipitates 
appears 
Chromium  To 10 drops of solution, add 1ml of 3% H2O2 
then add 6M NaOH dropwise untill the solution 
is basic. Heat in a boiling water bathh for a few 
minutes 
No  yellow solution of CrO4
2 
form 
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ACUTE ORAL TOXICITY STUDY OF RASA CHENDHURAM (PULIPANI) 
(OECD GUIDELINE – 423)     
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals 
of a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on 
average 2-4 steps may be necessary to allow judgement on the acute toxicity of 
the test substance.  
 This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed doses, 
adequately separated to enable a substance to be ranked for classification 
purposes and hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least 
two doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency and 
repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the acute 
toxicity of the test substance to enable its classification. The substance is administered 
orally to a group of experimental animals at one of the defined doses. The substance is 
tested using a stepwise procedure, each step using three animals of a single sex. 
Absence or presence of compound-related mortality of the animals dosed at one step 
will determine the next step, i.e. 
− no further testing is needed 
− dosing of three additional animals, with the same dose  
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− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance 
to one of a series of toxicity classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wistar albino rat, although other rodent 
species may be used. Healthy young adult animals are commonly used laboratory 
strains should be employed. Females should be nulliparous and non-pregnant. Each 
animal, at the commencement of its dosing, should be between 6 to 8 weeks old and the 
weight (150-200gm) should fall in an interval within±20 % of the mean weight of any 
previously dosed animals.  
 
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals may 
be group-caged by dose, but the number of animals per cage must not interfere with 
clear observations of each animal. 
 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions. 
 
Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS, Madhavaram, Chennai. All the animals were kept under standard 
environmental condition (22±3°C).  The animals had free access to water and standard 
pellet diet (Sai meera foods, Bangalore). 
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Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions 
Preparation for Acute Toxicity Studies 
Rats were deprived of food overnight (but not water 16-18 h) prior to 
administration of the, RASA CHENDHURAM (PULIPANI).  
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
 
IAEC No   : IAEC/XL VIII/30/CLBMCP/2016 
Test Substance  : RASA CHENDHURAM (PULIPANI) 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual   
                                marking by using Picric acid.  
Number of animals               : 3 Female/group,  
Route of administration       :   Oral  
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd, 
Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
                   provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.    
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days  
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Administration of Doses:  
 RASA CHENDHURAM (PULIPANI) was suspended in water and 
administered to the groups of wistar albino rats in a single oral dose by gavage using a 
feeding needle. The control group received an equal volume of the vehicle. Animals 
were fasted 12 hours prior to dosing. Following the period of fasting, the animals were 
weighed and then the test substance was administered. Three Female animals are used 
for each group. The dose level of 9mg/kg body weight was administered. After the 
substance has been administered, food was withheld for a further 3-4 hours. The 
principle of laboratory animal care was followed. Observations were made and 
recorded systematically and continuously as per the guideline after substance 
administration. The visual observations included skin changes, mobility, aggressively, 
sensitivity to sound and pain, as well as respiratory movements. Finally, the number of 
survivors was noted after 24 hrs and these animals were then monitored for a further 14 
days and observations made daily. The toxicological effect was assessed on the basis 
of mortality. 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
 
Observations include changes in skin and fur, eyes and mucous membranes, and 
also respiratory, circulatory, autonomic and central nervous systems, and somatomotor 
activity and behavior pattern. Attention was directed to observations of tremors, 
convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles and criteria 
summarized in the Humane Endpoints Guidance Document taken into consideration. 
Animals found in a moribund condition and animals showing severe pain or enduring 
signs of severe distress was humanly killed. When animals are killed for human reasons 
or found dead, the time of death was recorded. 
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Acute oral toxicity study of RASA CHENDHURAM (PULIPANI) 
Table 1: Dose finding experiment and its behavioral Signs of acute oral Toxicity 
 
Observation done: 
SL Group 
CONTROL 
Observation SL Group 
TEST GROUP 
Observation 
1 Body weight Normal 1 Body weight Normally increased 
 
2 Assessments of posture Normal 2 Assessments of 
posture 
Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of 
Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
7 Change in skin color No significant 
color change 
7 Change in skin 
color 
No significant color 
change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 
10 Sensitivity response Normal 10 Sensitivity 
response 
Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle 
gripness 
Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
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Behaviour: 
 The animals will be observed closely for behaviour in the first four hours which  
includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, catalepsy, 
convolusion, excitation, head twitches, lacrimation, loss of corneal reflex, loss of 
traction, piloerection  reactivity of touch, salivation, scratching, sedation, chewing,  
head movements, sniffing, straub, tremor and writhes, diarrhea, leathery, sleep and 
coma.  
 
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated dose 
groups.  
 
Mortality: 
           Animals were observed for mortality throughout the entire period. 
 
REPEATED DOSE 28-DAY ORAL TOXICITY (407) STUDY OF 
RASA CHENDHURAM (PULIPANI) 
Test Substance  : RASA CHENDHURAM (PULIPANI) 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-200gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number   and    individual  
   marking by using    Picric acid 
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd,       
       Bangalore 
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Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
                   provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.    
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
 
Table 5  
  
RCM - RASA CHENDHURAM (PULIPANI) 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for  28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior 
to the initiation of treatment. Each animal was marked with picric acid. The females 
were nulliparous and non-pregnant. 
 
Justification for Dose Selection: 
As per OECD guideline three dose levels were selected for the study. They are 
low dose (X), mid dose dose (5X), high dose (10X). X is calculated by multiplying the 
therapeutic dose (488mg) and the body surface area of the rat (0.018). i.e X dose is 
(9mg), 5X dose is 45mg/animal, 10X dose is 90mg/animal. 
Groups No of Rats 
Group I  Vehicle control (Water) 12(6male,6 female) 
Group II RCMp- low dose X (9mg) 12 (6male,6 female) 
Group III RCMp- Mid dose  5X (45mg) 12 (6male,6female) 
Group IV RCMp- High dose 10X( 90mg) 12(6male,6female) 
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RASA CHENDHURAM (PULIPANI) suspended in prescribed solvent, It 
was administered to animals at the dose levels of X, 5X, 10X. The test substance 
suspensions were freshly prepared every two days once for 28 days. The control 
animals were administered vehicle only. The drug was administered orally by using 
oral gavage once daily for 28 consecutive days. 
 
Observations: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course 
of study.  
Food and water Consumption: 
  Food and water consumed per animal was calculated for control and the treated 
dose groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of      
study. 
Necropsy: 
All the animals were sacrificed by excessive anaesthesia on day 29. Necropsy 
of all animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted 
over-night. Blood samples were collected from orbital sinus using sodium heparin 
(200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for Hematology as 
anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 minutes. 
Haematological Investigations: 
               Haematological parameters were determined using Haematology analyzer. 
 
  
Preparation and Administration of Dose:   
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Biochemical Investigations:  
              Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
              Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group 
than the low, then the mid dose group will also be examined. Organs will be collected 
from all animals and preserved in 10% buffered neutral formalin for 24 h and washed 
in running water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in 
an auto technicon and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten paraffin 
at 50°C and then in a cubical block of paraffin made by the “L” moulds. It was followed 
by microtome and the slides were stained with Haematoxylin-eosin red. 
 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, 
hematology and blood chemistry were subjected to One-way ANOVA followed by 
dunnet t test using a computer software programme – Graph pad  version 7.All data 
were summarized in tabular form, (Table-6 to 12) 
 
STUDY DESIGN:  
                            An Open Comparative Clinical Trial 
STUDY PLACE : 
                       OPD section of post graduate, sirappu maruthuvam department attached 
to Arignar Anna Government Hospital, Government Siddha Medical College, 
Arumbakkam, Chennai. 
 
DATA COLLECTION: 
    Literary evidence collected from various  
 Siddha literatures 
 Books on modern medicine 
 
TRIAL DRUGS: 
INTERNAL DRUG:  RASA CHENDHURAM , 65 mg , twice daily. 
EXTERNAL DRUG:  PALAGARAI KUZHAMBU   
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SAMPLE SIZE:  
               40 cases OPD 
 20 patients treated with internal drug alone 
 20 patients treated with internal and external drugs 
INCLUSION CRITERIA 
 Age: Between 18 - 60 years.  
 Sex: Both male and female 
 Hypo-pigmented patches with hyper pigmented border without any structural 
changes in any part of the body 
 Patient Willing to sign consent form. 
 Hypopigmentation due to Worm infestation 
 
EXCLUSION CRITERIA 
 Albinism 
 Leprosy 
 STD 
 HIV 
 Burns  
 Pregnancy and Lactation 
 Cardiac diseases 
 History of long term use of steroids. 
 
WITHDRAWAL CRITERIA 
 Intolerance to the drug and development of adverse reactions during the period 
of drug trial. 
Poor patient compliance & defaulters resulting in adverse events.  
ADR REPORTING 
If ADR is reported patients will be referred to SCRI (Peripheral Pharmaco vigilance 
centre) 
 
EVALUATION OF CLINICAL PARAMETERS: 
Patients are clinically evaluated by the following parameters. 
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HISTORY TAKING: 
Age , sex, occupation , socio economic status, complaints and its duration , 
previous illness , family history , personal habits were recorded in the case shet for 
every patient at the time of first visit to OP. 
 
MODERN INVESTIGATIONS: 
Blood: 
Hb,  TC, DC, ESR, Blood sugar  (R) 
Kidney Function Tests: 
Blood Urea, Serum Creatinine 
Liver Function Tests: 
Direct Bilirubin,  
Serum total bilirubin,  
In Direct bilirubin,  
SGOT,  SGPT 
Urine: 
Albumin,  
Sugar 
           Deposits 
 
ASSESSMENT TOOLS 
A. Clinical assessment: 
 
VITILIGO AREA SEVERITY INDEX (VASI): 
Its name is an adoption from PASI score in psoriasis. The percentage of vitiligo 
involvement is calculated in terms of hand units. One hand unit is approximately 
equivalent to 1% of the total body surface area. The degree of pigmentation is 
estimated to the nearest of one of the following percentages: 100% - complete 
depigmentation, no pigment is depigmentation]present; 90% - specks of pigment 
present; 75% - depigmented area exceeds the pigmented area; 50% - pigmented and 
depigmented areas are equal;  
 
25% - pigmented area exceeds depigmented area; and 10% - only specks of 
depigmentation present . The VASI for each body region is determined by 
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the product of the area of vitiligo in hand units and the extent of depigmentation within 
each hand unit measured patch. 
Total  
The VASI for each body region is determined by the product of the area of 
vitiligo in hand units and the extent of depigmentation within each hand unit measured 
patch. 
Total body VASI = S All body sites [Hand Units] ´ [Residual depigmentation] [1]. 
VASI score               ~−50              Very much worse  
VASI score               -50 -25           Much worse  
VASI score               -26 -10           Worse 
VASI score               -10  0              Minimally worse  
VASI score               0 10                Minimally improved  
VASI score               10 25              Improved 
VASI score               25 50              Much improved 
VASI score               +50~              Very much improved 
 
CALCULATION: 
The body is divided into four sections (head (H) (10% of a person's  skin); arms 
(A) (20%); trunk (T) (30%); legs (L) (40%)). Each of these areas is scored by itself, and 
then the four scores are combined into the final PASI. For each section, the percent of 
area of skin involved, is estimated and then transformed into a grade from 0 to 6: 
 
 0% of involved area, grade: 0 
 < 10% of involved area, grade: 1 
 10–29% of involved area, grade: 2 
 30–49% of involved area, grade: 3 
 50–69% of involved area, grade: 4 
 70–89% of involved area, grade: 5 
 90–100% of involved area, grade: 6 
 
Within each area, the severity is estimated by three clinical signs: erythema 
(redness),  induration (thickness) and desquamation (scaling). Severity parameters are 
measured on a scale of 0 to 4, from none to maximum. 
body VASI = S All body sites [Hand Units] ´ [Residual depigmentation] [1].
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The sum of all three severity parameters is then calculated for each section of 
skin, multiplied by the area score for that area and multiplied by weight of respective 
section (0.1 for head, 0.2 for arms, 0.3 for body and 0.4 for legs). 
 
B. Photo assessment: 
       Photos of the patient before and after treatment for clinical improvement evidence. 
DRUG STORAGE:  
 The trial drug is stored in clean air tight glass container (borosil container) and 
it is dispensed to the patients.  
DATA COLLECTION FORMS: 
 Required information will be collected from each patients by using following 
forms. 
Form I  : Screening and selection proforma 
Form II : History taking proforma 
Form III : Clinical assessment proforma 
Form IV   : Clinical assessment during and after trial 
Form V : Laboratory investigation proforma 
Form VI : Informed consent form 
Form VII   : Withdrawal form 
Form VIII : Patients information sheet  
 
STUDY ENROLLMENT 
In this study Patients reporting at the OPD with the clinical symptoms of Hypo 
pigmentation, itching, burning sensation etc will be examined clinically for enrolling 
in the study based on the inclusion and exclusion criteria.  
 The patients who are to be enrolled would be informed (Form IV) about the 
study, trial drug, possible outcomes and the objectives of the study in the language and 
terms understandable to them. 
After ascertaining the patient’s willingness, informed consent would be 
obtained in writing from them in the consent form (Form IV). All these patients will be 
Address, Phone number and Doctors phone number etc. will be given, so as to report 
easily should any complications arise. 
given unique registration card in which patients Registration number of the study, 
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             Complete clinical history, complaints and duration, examination findings-- all 
would be recorded in the prescribed Proforma in the history and clinical assessment 
forms separately. Screening Form- I will be filled up: Form –II and Form –III will be 
and laboratory investigations respectively. Patients would be advised to take the trial 
drug and appropriate dietary advice (Form IV-D) would be given according to the 
 
CONDUCT OF THE STUDY: 
 Patients satisfying the inclusion and exclusion criteria will be included in the 
trial.  
treatment. Photos will be taken before and after the treatment. 
 At the end of the study the trial patients are advised to report when there is 
reoccurrence.  
 
DATA ANALYSIS: 
 After enrolling the patients in the study, a separate file for each patient will be 
maintained and all forms will be kept in the file. Whenever the patients visits OPD 
during the study period necessary entries will be made in the assessment forms. The 
data entries and adverse events if any will be monitored by the head of the department.  
 
Primary Outcome  
  The therapeutic efficacy of trial drugs will be assessed by   repigmentation and 
also by reduction in the size. 
 VASI Score (Vitiligo area scoring index) 
 To evaluate the prevention of recurrence by follow-up after two months from 
the start of intervention. 
            To evaluate the days of outcome with in the treatment of 48 days.  
Secondary Outcome:  
Secondary outcome is assessed by comparing the safety parameters before and after 
treatment.  
  
used for recording the patients history, clinical examination of symptoms and signs 
patients perfect understanding.  
            Modern investigations will be carried out before treatment and at the end of the 
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ADR REPORTING 
  If ADR is reported patients will be referred to SCRI (Peripheral Pharmaco vigilance 
centre)  
 
ETHICAL ISSUES: 
• Informed consent will be obtained from the patients after explaining about the 
clinical trial in regional tongue. 
• After the consent of the patient (through consent form) if they are in the  
inclusion criteria they will be enrolled in the study. 
• Treatment will be provided free of cost. 
• Concomitant medications will be given when required. 
• Rescue medications will be given when needed. 
• The patients who are excluded (as per exclusion criteria) are given proper 
treatment with full care at OPD. 
 
     RESULTS AND OBSERVATION     
 RASA CHENDHURAM  ORGANOLEPTIC  CHARACTORS 
COLOR OF THE INGREDIENTS 
RASA CHENDHURAM - PHYSICOCHEMICAL  ANALYSIS  RESULT 
CHARACTERS RESULTS 
Colour Dark  red 
Odour Oderless 
Taste Tasteless 
Appearance Fine powder 
Solubility Sparingly soluble in both water and 
alcohol 
S.NO RAW DRUGS BEFORE PURIFICATION AFTER 
PURIFICATION 
1 Gandhagam Yellow solid Yellow granules 
2 Rasam Colourless, dust floated Colourless 
3. Thalagam Bright yellow Yellow 
S.NO NAME OF EXPERIMENT VALUE 
1 Loss on drying      0 % 
2. Total ash 91.5 % 
3. Water soluable ash 29 % 
4. Acid insoluable ash 48 % 
5. pH value (10%) 1.47 
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  TRADITIONAL TESTING METHODS FOR CHENDHURAM 
S.NO TESTS INFERENCE 
1. Floating on water + 
2. Finger furrows test + 
3. Lusterless + 
4. Tasteless + 
5. Colour Dark red 
QUALITATIVE ANALYSIS OF HEAVY METALS 
S.NO HEAVY METAL RESULT 
1 LEAD ND 
2 MERCURY ND 
3 ARSENIC ND 
4 CADMIUM ND 
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ACUTE ORAL TOXICITY STUDY OF RASA CHENDHURAM 
(PULIPANI) 
Results: 
All data were summarized in tabular form, (Table-1-4) showing for each test group the 
number of animals used, the number of animals displaying signs of toxicity, the number of 
animals found dead during the test ,description of toxic symptoms,, weight changes, food and 
water intake 
No of animals in each group:3 
Table 2 (Observational study Results) 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
9mg 
+ - - + - + - - - - - - - - - - - - - - 
1. Alertness  2. Aggressive ness   3. Pile erection   4. Grooming   5.Gripping   6. Touch
Response 7. Decreased Motor Activity   8.Tremors   9. Convulsions  10. Muscle Spasm   11. 
Catatonia  12.Muscle relaxant 13. Hypnosis  14.Analgesia 15.Lacrimation 16.Exophthalmos 
17.Diarrhea 18. Writhing 19. Respiration 20. Mortality.
(+  Present, -  Absent) 
Table 3 ( Body weight Observation) 
Table 3 (Water intake (ml/day) of Wistar albino rats group exposed to RASA 
DOSE 
DAYS 
1 7 14 
CONTROL 280.2±42.30 281.4 ± 64.12 282.6 ±26.18 
HIGH DOSE 280.4± 21.24 281 ± 3.64 281.4 ± 2 
P value (p)* NS NS NS 
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CHENDHURAM (PULIPANI): 
DOSE DAYS 
1 6 14 
CONTROL 61 ± 1.12 62±2.22 63.9±1.14 
HIGH DOSE 62.2±1.1 63±1.14  64.20±24 
P value (p)* NS NS NS 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
Table 4: Food  intake (gm/day) of Wistar albino rats group exposed to RASA 
CHENDHURAM (PULIPANI)     
DOSE DAYS 
1 7 14 
CONTROL 56.24±2.22 56.2±7.42 58.4±3.46 
High DOSE 60.6±1.63 60.6±2.62 64.1±5.38 
RESULTS 
Repeated Dose 28- day oral toxic study of RASA CHENDHURAM 
(PULIPANI) 
Table 6: Body weight of wistar albino rats group exposed to RASA CHENDHURAM 
(PULIPANI) 
DOSE 
DAYS 
1 7 14 21 28 
CONTROL 230.2±15.45 231.5 ± 25.15 231.5 ± 15.50 232.5± 15.16 232.4 ± 15.15 
LOW DOSE 235.2 ± 15.15 235.7 ± 32.22 236.6± 46.14 236 ± 62.18 236.41± 15.24 
MID DOSE 200.4± 06.64 200.3 ± 16.24 201.2 ± 18.12 
201.2 ± 
11.26 
202.4 ± 24.10 
HIGH DOSE 210.6± 24.24 210.6 ± 10.42 211.4 ± 12.24 211 ± 14.38 212 ± 54.61 
P value (p)* NS NS NS NS NS 
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NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
Table 7: Water intake (ml/day) of Wistar albino rats group exposed to RASA CHENDHURAM 
(PULIPANI) 
DOSE DAYS 
1 6 14 21 28 
CONTROL 50.1 ± 4.32 50±4.12 50.2±1.10 50±1.12 50.4±1.12 
LOW DOSE 52.1±1.11 52.8±2.22 52.6±1.42 53.2±2.26 52.4±1.21 
MID DOSE 53.1±1.12 53.3±1.11 53.1±2.21 53.4±1.12 53.4±1.42 
HIGH DOSE 54.1±1.41 54.2±1.42 54.4±1.44 54.6±1.52 55.8±2.82 
P value (p)* NS NS NS NS NS 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
Table 8: Food intake (gm/day) of Wistar albino rats group exposed to RASA 
CHENDHURAM (PULIPANI)      
DOSE DAYS 
2 7 23 22 28 
CONTROL 30±5.14 31.2±2.12 31.3±2.18 31.2±1.14 32±2.12 
LOW DOSE 30.2±1.14 31.3±1.31 31.1±1.21 31.5±1.32 31.5±1.62 
MID DOSE 32.1±2.22 32.2±3.40 32.2±2.24 32.2±2.16 33.2±1.24 
HIGH DOSE 33.1±1.12 33.1±1.14 33.6±2.26 34.2±1.10 34.6±3.42 
P value (p)* NS NS NS NS NS 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test 
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Table 9: Haematological parameters of Wistar albino rats group exposed to RASA 
CHENDHURAM (PULIPANI) 
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin(g/dl) 16.7±0.71 16.60±0.24 16.5±0.23 16.82±0.16 N.S 
Total WBC (×103
l) 
10.81±0.32 10.64±0.21 10.54±0.42 9.60±1.12 N.S 
Neutrophils (%) 31.12±0.01 31.02±0.12 32.11±1.22 33.02±6.21 N.S 
lymphocyte (%) 72.12±1.24 72.12±1.32 73.10±2.34 73.20±2.44 N.S 
Monocyte (%) 0.9±0.02 0.9±0.01 0.9±0.04 0.9±0.03 N.S 
Eosinophil (%) 0.5±0.03 0.5±0.04 0.5±0.05 0.5±0.08 N.S 
Platelets cells103/µl 680.17±3.13 682.41±4.12 682.13±2.02 684.10±2.34 N.S 
Total RBC 106/µl 8.42±0.12 8.46±0.53 8.49±0.44 8.74±0.46 N.S 
PCV% 42.12±0.2 42.62±1.02 43±1.20 44.40±2.10 N.S 
MCHC g/dL 34.5±1.20 34.2±1.10 34.8±1.70 34.33±1.30 N.S 
MCV fL(µm3) 58.2±4.02 59.2±1.10 58.9±1.40 58.8±1.20 N.S 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 Table 10 : Biochemical Parameters of of Wistar albino rats group exposed to RASA 
CHENDHURAM (PULIPANI)      
BIOCHEMICAL 
PARAMETERS 
CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
GLUCOSE (R) (mg/dl) 125.11±3.2 125.12±2.10 
126.10±13.0
8 
128.12±4.2 N.S 
T.CHOLESTEROL(mg/dl) 120.16±1.20 120.25±1.30 122.60±1.18 123.24±1.30 N.S 
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TRIGLY(mg/dl) 54.16±1.52 54.12±1.42 56.15±1.23 56.16±1.23 N.S 
LDL 72.4±2.14 72.12±2.54 73.10±1.32  73.24±10.20 NS 
VLDL 11.2±1.30 11.20±2.21 11.22±1.24 11.14±12.14 NS 
HDL 27.14±6.12 27.42±2.30 28.16±2.60 28.17±2.14 NS 
Ratio 
1(T.CHO/HDL) 
3.41±1.16 3.42±1.40 3.74±1.04 3.64±2.03 NS 
Ratio 2(LDL/HDL) 1.92±1.14 1.91±1.12 1.71±2.20 1.96±08.02 NS 
Albumin (g/dL) 
5.43±0.16 5.50±0.52 5.04±9.30 
5.42±9.48 
NS 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test 
Table 11: Renal function test of of Wistar albino rats group exposed to RASA 
CHENDHURAM (PULIPANI)      
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 26.70±0.19 26.50±0.26 27.16±1.28 27.68±1.24 N.S 
CREATININE(mg/dl) 0.22±0.02 0.21±0.04 0.22±0.05 0.24±0.07 N.S 
BUN(mg/dL) 17.1±0.01 17.10±0.64 17.6±0.52 17.86±1.02 NS 
URIC ACID(mg/dl) 6.04±0.34 6.06±0.51 6.6±0.15 6.42±0.20 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
Table 12: Liver Function Test of of Wistar albino rats group exposed to Rasa 
Chendhuram (Pulipani)  
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
T BILIRUBIN(mg/dl). 0.07±0.01 0.07±0.02 0.07±0.01 0.07±0.03 N.S 
SGOT/AST(U/L) 81.14±1.63 81.31±0.02 82.01±1.24 82.64±1.63 N.S 
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SGPT/ALT(U/L) 78.12±1.08 78.21±1.24 78.14±1.26 77.68±0.01 N.S 
ALP(U/L) 119.21±3.16 119±32.10 119±12.14 120.03±8.32 N.S 
T.PROTEIN(g/dL) 6.2.10±0.04 6.2±0.11 6.2±0.10 6.4±0.46 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test. 
HISTO PATHOLOGY 
CONTROL GROUP 
High dose 
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 Kidney                             Liver            Spleen 
Kidney          Liver Spleen 
 1. AGE 
 
 
 
S. No 
 
 
AGE( In years) 
 
 
NO. OF CASES (Out of 40) 
 
 
PERCENTAGE (%) 
 
1. 
 
18-20 Years 
 
4 
 
10% 
 
2. 
 
21-30 Years 
 
9 
 
22.5% 
 
3. 
 
31-40Years 
 
8 
 
20% 
 
4. 
 
41-50years 
 
12 
 
30% 
 
5. 
 
51-60years 
 
7 
 
17.5% 
 
 
 
Inference: 
Out of 40 cases, 4(10%) of cases belonged to the age group of 18-20 years, 9 
(22.5%) of cases belonged to the age group of 21-30 years, 12 (30%) of cases belonged 
to the age group of 31-40 years, 11(27.5%) of cases belonged to the age group of 41-
50 years, and 7(17.5%) of cases belonged to the age group of 51-60 years. 
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2. GENDER DISTRIBUTION
S. No GENDER NUMBER OF CASES PERCENTAGE 
(%) 
1 Male 18 45% 
2 Female 22 55% 
Inference: 
Out of 40 cases, 18(45%) were Male, 22(55%) cases were Female. 
45%
55%
Gender distribution
Male
Female
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 3. DIETARY HABITS 
 
 
S. No 
 
DIET 
 
NUMBER OF  
CASES 
 
PERCENTAGE (%) 
 
1 
 
Vegetarian 
 
7 
 
17.5% 
 
2 
 
Mixed diet 
 
33 
 
82.5% 
 
 
 
 
 
Inference: 
 
Out of 40 cases 7 (17.5%) of cases were Vegetarians and 33 (82.5 ) cases 
were  Non- vegetarians. 
17.5%
82.5%
Diet
Veg
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4. OCCUPATION
S.No OCCUPATION NUMBER OF 
CASES 
PERCENTAGE (%) 
1 Office worker 9 22.5% 
2 Home maker 15 37.5% 
3 Business 4 10% 
4 Student 8 20% 
5 Farmer 0 0% 
6 Others 4 10% 
Inference: 
Out of 40 cases 8 (20 %) were Student, 15 (37.5%)  were Homemaker, 9 
(22.5%) were Office Workers, 4 (10%)were businessmen, 0 (0 %) were farmer, 4 
(10%) were others 
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5. SOCIO – ECONOMIC STATUS 
 
S.No SOCIO – ECONOMIC 
STATUS 
NUMBER OF 
CASES 
PERCENTAGE (%) 
1 Low Income  
 
27 67.5% 
2 Moderate Income  9 22.5% 
3   High Income  4 10% 
 
 
 
Inference: 
Among 40 cases 67.5% comes under low economic status, 22.5% of them under 
moderate status and 10% of them under high income status. 
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6. FAMILY HISTORY:
FAMILY HISTORY NUMBER OF CASES PERCENTAGE 
PRESENT 4 10% 
ABSENT 36         90% 
Inference: 
Out of 40 cases 4 (10 %) of cases have family history and 36 (90%)of 
cases have no family history. 
10 %
90 %
Family History
Present
Absent
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7 .DISTRIBUTION OF THINAI 
S.No THINAI NUMBER OF CASES PERCENTAGE (%) 
1 Kurinji 0 0% 
2 Mullai 0 0% 
3 Marutham 4 10% 
4 Neithal 36 90% 
5 Paalai 0 0% 
Inference: 
Out the 40 patients, no patients were recorded from kurinchi ,mullai and 
Paalai thinai, 4(10%) of cases from Marutham thinai, 36(90%) from Neithal 
thinai. 
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8.  PARUVAKAALAMDISTRIBUTION: 
 
S.No KAALAM (Season) NUMBER OF CASES PERCENTAGE (%) 
1 Kaarkaalam 
( Mid Aug – Mid Oct) 
5 12.5% 
2 koothirKaalam 
(Mid Oct – Mid Dec) 
8 20% 
3 Munpanikaalam 
(Mid Dec – Mid Feb) 
11 27.5% 
4 Pinpanikaalam 
(Mid Feb – Mid Apr) 
6 15% 
5 Elavenirkaalam 
(Mid Apr – Mid Jun) 
3   7.5% 
6 Muthuvenirkaalam 
(Mid Jun – Mid Aug) 
7                   17.5% 
 
 
 
Inference: 
 
Out of 40 cases, 5 patients  (12.5 %) were recorded in Karkaalam, 8 patients 
(20%) were recorded in Koothir Kaalam, 11 patients (27.5%) were recorded in Munpani 
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Kaalam, 6 patients (15%) were recorded in Pinpani Kaalam, 3 patients   (7.5%) were 
recorded in Elavenil Kaalam and 7 patients (17.5%) were recorded in Mudhuvenil 
Kaalam. 
9. EZHU UDALKATTUGAL
S.NO   UDAL KATTUGAL No. ofCases Percentage 
1. Saaram 40        100% 
2. Senneer 40 100% 
3. Oon 15 37.5 % 
4. Kozhuppu 15 37.5 % 
5. Enbu - - 
6. Moolai - - 
7. SukkilamSuronitham - - 
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Inference: 
Out of 40 cases Saaram was affected in all the 40 cases (100%), Senneer in 40 
cases (75%) and oon  in 15 cases , kozhuppu in 15 cases (37.5)  and  no other changes 
seen in other Udal Kattugal. 
10. DISTRIBUTION OF MUKKUTRAM:
A. Derangement in the types of Vatham 
S.No Classification of vatham No. of Cases Percentage 
1. Piranan - - 
2. Abanan 18 45 % 
3. Viyanan 15 37.5% 
4. Uthanan - - 
5. Samanan 40 100 
6. Nagan - - 
7. Koorman 
8. Kirukaran - - 
9. Devathathan - - 
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Inference: 
A. Vatham: 
Out of 40 cases Abanan was affected in 18 (45%) of cases. Viyanan was affected in 
15 (37.5%) of cases and Samanan was affected in 40 (100%) of cases 
  
 
 
                      B.Derangement in types of Pitham
 
 
 
 
 
S.No Types of pitham No. of Cases Percentage 
1. Analapitham - - 
2. Ranjagam 20 50 
3. Saathagam - - 
4. Prasagam 40 100 
5. Alosagam - - 
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B.Inference: 
Pitham:   Ranjagam was affected in 20 of cases (50%) and Prasagam was 
affected in all the 40 (100%) of cases. 
3. DERANGEMENT IN TYPES OF KABAM :
S.No KABAM NUMBER OF CASES PERCENTAGE (%) 
1 Avalambagam 15 37.5% 
2 Klethagam 0 0% 
3 Pothagam 0 0% 
4 Tharpagam 0 0% 
5 Santhigam 15 37.5% 
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Inference: 
Out of 40 patients, Avalambagam was affected in 15 patients (37.5%), 
Santhigam was affected in 15 patients (37.5%). 
  
11. EN VAGAI THERVUGAL 
 
 
S.No EN VAGAI THERVUGAL NUMBER OF CASES PERCENTAGE (%) 
1 Naa 12 30% 
2 Niram 40 100% 
3 Mozhi 0 0% 
4 Vizhi 0 0% 
5 Sparisam 0 0% 
6 Malam 15 37.5% 
7 Moothiram 0 0% 
 
 
Inference: 
 
Out of 40 patients, naa was affected in  12 cases (30 %) niram  was 
affected in all the 40 (100%) cases;  Malam was affected in 15 (37.5%) cases. 
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12 .SITE OF LESIONS : 
SITE OF LESIONS NO OF CASES 
OUT OF 40 
PERCENTAGE(%) 
Scalp 0 0% 
Face 12 30% 
Lips 4 10% 
Abdomen 3 7.5% 
Upper limb 9 22.5% 
Lower limb 5 12.5% 
Multiple 7 17.5% 
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Inference : 
 Out of  40 patients 12 patients (30 %) were affected in the face , 3 patients 
(7.5%) were affected in the  abdomen , 13 patients (7.5%) were affected in the  upper 
limb ,  patients (12.5 %) were affected in the  lower limb, 7 patients (17.5%) were 
affected in the  multiple 
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13  .DURATION OF DISEASE 
DURATION OF DISEASE NO OF CASES PERCENTAGE 
10 Years 3 7.5% 
6 Years 1 2.5% 
5 Years 5 12.5% 
4 Years 3 7.5% 
3 Years 6 15% 
2 Years 7 17.5% 
1 Year 6 15% 
6 Month 8 20% 
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Inference: 
The higher incidence of  illness is 6 month of duration. 
14 .NAADI 
S.No NAADI NUMBER OF CASES PERCENTAGE (%) 
1 ValiAzhal 18 45% 
2 ValiIyam 4 10% 
3 AzhalVali 12 30% 
4 AzhalIyam 2 5% 
      5 IyaVatham 2 5% 
      6 IyaVali 2 5% 
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Inference: 
Out of 40  patients 18 patients (45%) had Valiazhal naadi, 4  patients (10%) had  
ValiIyam naadi,  12 patients (30%) had Azhalvali naadi, 2 Patient (5%) had Azhaliyam 
naadi, 2 Patienst (5%) had Iyavatham naadi, 2 patients  (5%) had Iyavali naadi. 
 . 
13. NEERKKURI: 
 
 
 
 
 
S.No 
 
 
Niram 
 
 
No. ofCases 
 
 
Percentage 
1. 
 
Straw colour 10 25 
2. 
 
Yellow colour 27 67.5 
3. Pale yellow colour 3 7.5 
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Inference: 
Out of 40 cases, 10 (25%) of cases showed straw coloured urine, 27 
(67.5%) of cases showed yellow coloured urine, 3 (7.5%) of cases showed Pale 
yellow coloured urine. 
14. NEIKKURI
S. No THATHU NEIKURI NUMBER OF 
CASES 
PERCENTAGE 
(%) 
1 Vathaneer Spread like snake 9 22.5% 
2 Pithaneer Spread like Ring 27 67.5% 
3 Kabhaneer Spread like pearl 4 100% 
Inference: 
Out of 40 cases 9 (22.5%) of patients showed Vatham type of neikkuri 
pattern, 27 (67.5) of patients showed Pitham type of neikkuri pattern and 4 
(10%) of patients showed Kabam type of neikkuri pattern. 
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15. MODERNCLASSIFICATION:
S. No Classification No. of cases Percentage 
1. Generalised 
8 20 
2. Localised 
30 75 
3. Segmental 
2 5 
Inference: 
Out of 40 cases Generalised vitiligo was seen in 8 (20%) cases, Localized 
vitiligo in 30 (75%) cases, Segmental Vitiligo in 2 (5%) cases. 
20 %
75 %
5 %
Modern classification
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16. PRECIPITATING FACTORS
S. No 
PRECIPITATING 
FACTORS 
No. of Cases Percentage 
1. Stress 26 65 
2. Anemia 10 25 
3. Injury 4 10 
Inference: 
Out of 40 cases, Stress precipitated Vitiligoin 26 (65%) cases, Anemia 
precipitated Vitiligo in 10 (25%) cases and Injury precipitated Vitiligo in 2 (10%) 
cases.
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17. CLINICAL FEATURES
SIGN AND 
SYMPTOMS 
BEFORE TREATMENT AFTER TREATMENT 
NO.OF 
CASES 
PERCENTAGE 
(%) 
NO.OF CASES PERCENTAGES 
(%) 
Hypopigmentation 
patches in skin    
40           100% 30 75% 
Depigmentation of  
hair 
         7 17.5 % 4 10% 
Itching 0 0% 0 0% 
Erythema 0 0% 0 0% 
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17. RESULTS
A. PATIENTS TREATED WITH BOTH TRAIL DRUGS (20 PATIENTS) 
S. No Result No. of Cases Percentage % 
1 Mild 2 10 
2 Moderate 3 15 
3 Marked 14 70 
4 Poor 1 5 
Inference: 
Out of 20 patients treated with internal and external drug, 2 (10%) case 
showed mild improvement, 3 (15%) cases showed moderate improvement, 14 (70%) 
showed marked improvement, 1(5 %) case showed poor improvement. 
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B. PATIENTS TREATED WITH INTERNAL TRAIL DRUG  (20 
PATIENTS) 
S. No Result No. of Cases Percentage% 
1 Mild 2 10 
2 Moderate 4 20 
3 Marked  12 60 
4 poor 2 10 
Inference: 
20 patients treated with internal drug, which yield Mild Improvement in 2 [ 10%) cases, 
Moderate Improvement in 4 (20%) cases, Marked Improvement in 12 (60%) cases and poor 
improvement in 2(10%) cases were noted. 
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C.COMPARISION OF RESULTS: 
PATIENTS TREATED WITH BOTH DRUGS (20 Pts) AND INTERNAL 
DRUG ALONE(20 Pts) 
S.No Results 
Both Drug Internal Drug only 
No. ofCases Percentage% No. ofCases Percentage% 
1 Mild 2 10 2 10 
2 Moderate 3 15  4 20 
3 Marked 14 70           12 60 
4 poor 1 5 2  10 
Inference: 
The higher incidence is Marked improvement occurs in administration of both 
drugs (70%)  than internal drug alone (60%). 
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D. RESULTS AFTER TREATMENT 
S. No Results No. of Cases Percentage 
1. Mild 4  10 
2. Moderate 7 17.5 
3. Marked 28 70 
4. Poor 1 2.5 
Inference: 
Out of 40 cases, 4 (10 %) of cases showed Mild improvement,7 (17.5%) of cases 
showed  Moderate improvement, 28 (70 %)of cases showed Marked improvement and
1 (2.5%) of case showed Poor improvement. 
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OP NO : 5739  AGE /SEX: 24/ F 
 BEFORE  TREATMENT  DURING TREATMENT 
 AFTER TREATMENT 
111
OP.NO  - 6020  AGE/SEX – 58/ M 
BEFORE TREATMENT DURING TREATMENT 
AFTER TREATMENT 
112
OP.NO – 2068  AGE/SEX – 23/M 
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CLINICAL PROGNOSIS 
LIVER FUNCTION TESTS FOR OPD PATIENTS TREATED WITH INTERNAL MEDICINE 
RASA CHENDHURAM  (INT) AND PALAGARAIKUZHAMBU (EXT) 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 23.20±9.07 18.25±5.32 0.065 
3 SGOT 19.50±5.40 17.70±7.78 0.309 
4 Total bilirubin 0.64±0.12 0.68±0.20 0.433 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
LIVER FUNCTION TESTS FOR OPD PATIENTS TREATED WITH INTERNAL MEDICINE 
RASA CHENDHURAM  (INT)  
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 22.50±11.02 21.80±7.36 0.763 
3 SGOT 19.92±6.70 20.05±6.78 0.955 
4 Total bilirubin 0.76±0.27 0.71±0.20 0.643 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
RFT FOR OPD PATIENTS TREATED WITH INTERNAL MEDICINE RASA CHENDHURAM 
(INT) PALAGARAIKUZHAMBU (EXT) 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 21.10±5.54 21.45±4.27 0.833 
2 Creatinine 0.58±0.17 0.67±0.12 <0.05 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
RFT FOR OPD PATIENTS TREATED WITH INTERNAL MEDICINE RASA CHENDHURAM 
(INT) 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 19.75±4.67 20.00±5.73 0.843 
2 Creatinine 0.73±0.19 0.74±0.15 0.694 
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C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
BLOOD ANALYSIS FOR OPD PATIENTS TREATED WITH INTERNAL MEDICINE RASA 
CHENDHURAM  (INT) PALAGARAIKUZHAMBU (EXT) 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 12.49±1.27 13.02±1.01 <0.001 
2 ESR1hr 28.85±14.87 7.20±4.22 <0.001 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
BLOOD ANALYSIS FOR OPD PATIENTS TREATED WITH INTERNAL MEDICINE RASA 
CHENDHURAM  (INT) 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 11.90±1.77 12.99±1.34 <0.001 
2 ESR1 hr 24.85±21.33 7.90±7.41 <0.05 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
VASI SCORE FOR OPD PATIENTS TREATED WITH INTERNAL MEDICINE RASA 
CHENDHURAM  (INT) PALAGARAI KUZHAMBU (EXT) 
S.No. BT 
VASI 
Score 
AT 
VASI 
Score 
1 0.1 0.1 
2 0.4 0.1 
3 0.6 0 
4 0.6 0.1 
5 3 0.6 
6 1.6 0.4 
7 0.8 0.2 
8 0.8 0.2 
9 0.8 0.2 
10 0.8 0.1 
11 1.2 0.4 
12 2.4 0 
13 1.8 0.3 
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14 0.3 0.3 
15 1.2 0 
16 3.6 0.8 
17 1.6 0.4 
18 1.6 0.4 
19 2.4 0.8 
20 2.4 0.8 
Software: spss17 version 
Variables: VASI Score – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.734 
Before and after treatment mean difference: 1.09 ± 0.78. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant reducing of 
VASI Score among the patients for the treatment of Venpulli (Vitiligo). Hence it is concluded 
that the treatment was effective and significant.  
VASI SCORE FOR OPD PATIENTS TREATED WITH INTERNAL MEDICINE RASA 
CHENDHURAM  (INT) 
S.No. BT 
VASI 
Score 
AT 
VASI 
Score 
1 3 0.6 
2 1.6 0.4 
3 1.2 0.4 
4 2.4 0 
5 0.4 0.1 
6 0.6 0 
7 0.6 0.1 
8 1.6 0.4 
9 2.4 0.8 
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10 1.8 0.3 
11 0.3 0.3 
12 1.2 0 
13 0.8 0.2 
14 0.8 0.1 
15 3.6 0.8 
16 1.6 0.4 
17 0.4 0.1 
18 0.6 0 
19 0.3 0.3 
20 1.2 0 
Software: spss17 version 
Variables: VASI Score – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.685 
Before and after treatment mean difference: 1.05 ± 0.78. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant reducing of 
VASI Score among the patients for the treatment of Venpulli (Vitiligo). Hence it is concluded 
that the treatment was effective and significant.  
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DISCUSSION 
 Skin disease is often easily noticeable than other disease. Appearance 
of the skin can determine the status of each individual incarnation of himself .Due to 
changes in a person’s appearance, venpulli (vitiligo) patients often experience 
psychological stress and suffer from social stigma. 
Yugi vaithiya chinthamani mention venpulli noi as swetha kuttam which 
comes under the eighteen types of  kuttam. As the term kuttam bears social stigma, 
the disease is called  as venpulli. 
The clinical entity of venpulli noi is more or less similar to that of 
vitiligo in modern medicine. Vitiligo is an acquired, idiopathic, depigmentory 
condition of skin and hair varying sizes and shapes. It  is varying sizes and shapes. 
Besides loss of colour there is no other structural change. 
The author has collected information largely from various siddha and 
modern textbook. 40 patients were selected from Govt Siddha Medical College 
OPD on both siddha and modern diagnostic method under the investigation of my 
guide. 
The trial drugs for this study were prepared by the Author in the 
Gunapadam practical lab, Govt Siddha Medical College, under the supervision of 
the members of the teaching faculty and guided by the Head of the Department of 
Sirappu Maruthuvam, Govt Siddha Medical College, Arumbakkam, Chennai -106. 
The trial drugs Rasa  Chenduram (Internal) and palagarai kuzhambu (External) were 
given for 48 days.  Out-Patients were asked to visit the hospital once in 7 days. For 
Out-Patients the drugs were given for 48 days and the clinical assessment was done 
on 0
th
day, 8
th 
day, 15
th 
day, 22
th 
day 29
th 
day, 36th day, 43rdday, 48thday. 
      Patients were instructed to take the medicines regularly and apply the 
external medicine twice a day and to expose the affected parts to sunlight in the 
morning. It was ensured that the diet restrictions such as non citric acid foods. 
imposed were followed properly by the patients. Before and after the course of 
treatment, the patients were subjected to laboratory investigations and photographs 
were taken. 
Based on various criterias, the datas were collected and tabulate 
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DISTRIBUTION  ACCORDING TO AGE : 
 Out of 40 cases, 4 (10%) of cases belonged to the age group of 18-20 
years. 
 9 (22.5%) of cases belonged to the age group of 21-30 years. 
 12 (30%) of cases belonged to the age group of 31-40 years 
 11 (27.5%) of cases belonged to the age group of 41-50 years 
 7 (17.5%) of cases belonged to the age group of 51-60 years. 
DISTRIBUTION   ACCORDING TO GENDER: 
 18(45%) were Male, 
 22 (55%) cases were Female. 
DISTRIBUTION   ACCORDING  TO DIETARY HABITS : 
 Out of 40 cases 7(17.5%) of cases were Vegetarians
 33 (82.5 %) cases were Non- vegetarians.
DISTRIBUTION  ACCORDING   TO  OCCUPATION : 
 8  (20 %) were Student 
 15 (37.5%)   were Home maker, 
 9 (22.5%) were Office Workers 
 4 (10%) were businessmen 
 4 ( 10%) were others 
DISTRIBUTION  ACCORDING   TO SOCIO – ECONOMIC STATUS 
 67.5% comes under low economic status
 22.5% of them under moderate status
 10 % of them under high income status.
DISTRIBUTION  ACCORDING   TO FAMILY HISTORY : 
 36 (90%) of cases have no family history.
 4 (10 %) of cases have family history
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DISTRIBUTION  ACCORDING   TO THINAI: 
 36 (90%) from Neithal thinai.
 4 (10%) of cases from Marutham thinai,
DISTRIBUTION  ACCORDING   TO PARUVAKAALAM 
 5 patients  (12.5 %) were recorded in Karkaalam,
 8 patients (20%) were recorded in Koothir Kaalam,
 11 patients (27.5%) were recorded in Munpani Kaalam,
 6 patients (15%) were recorded in Pinpani Kaalam,
 3  patients (7.5 %) were recorded in Elavenil Kaalam
 7 patients (17.5%) were recorded in Mudhuvenil Kaalam
DISTRIBUTION  ACCORDING   TO EZHU UDAL KATTUGAL 
 Saaram was affected in all the 40 cases (100%)
 Senneer was affected in 40 cases (75%)
 oon was affected in 15 cases
 kozhuppu in was affected 15 cases (37.5)
DISTRIBUTION  ACCORDING   TO  MUKKUTRAM 
A.  Vatham: 
 Abanan was affected in 18 (45%) of cases. 
 Viyanan was affected in 15 (37.5%) of cases 
 Samanan was affected in 40(100%) of cases 
 Ranjagam was affected in 20 of cases  (50%) 
 Prasagam was affected in all the 40 (100%) of cases. 
 Avalambagam was affected in 15 patients (37.5%) 
 Santhigam was affected in 15 patients (37.5%). 
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C. Kabam
B. Pitham: 
DISTRIBUTION  ACCORDING   TO  EN VAGAI THERVUGAL 
 naa was affected in  12 cases  (30 %)  
 niram was affected in all the 40 (100 %) cases 
 Malam was affected in 15 (37.5%) cases. 
DISTRIBUTION  ACCORDING   TO NAADI 
 18 patients (45%) had Valiazhal naadi 
 4  patients (10%) had  ValiIyam naadi, 
 12 patients (30%) had Azhalvali naadi 
 2 Patient (5%) had Azhaliyam naadi, 
 2 Patienst (5%) had Iyavathamnaadi 
 2 patients  (5%) had Iyavalinaadi . 
DISTRIBUTION  ACCORDING   TO  NEERKKURI: 
 10 (25%) of cases showed straw coloured urine 
 27 (67.5%) of cases showed yellow coloured urine 
 3 (7.5%) of cases showed Pale yellow coloured urine. 
DISTRIBUTION  ACCORDING   TO  NEIKKURI : 
 9 (22.5%) of patients showed Vatham type of neikkuri pattern 
 27 (67.5) of patients showed Pitham type of neikkuri pattern 
 4 (10%) of patients showed Kabam type of neikkuri pattern. . 
DISTRIBUTION ACCORDING TO PRECIPITATING FACTORS : 
 Stress  precipitated  Vitiligo  in  26 (65%)  cases 
 Anemia precipitated Vitiligo in 10 (25%) cases 
 Injury precipitated Vitiligo in 2 (10%) cases. 
129
RESULTS 
A.PATIENTS TREATED WITH BOTH TRAIL DRUGS (20 PATIENTS) 
 2 (10%) case showed   mild   improvement 
 3 (15%)  cases   showed  moderate  improvement 
 14 (70%) showed marked improvement 
 1 (5 %) case showed poor improvement 
B. PATIENTS TREATED   WITH  INTERNAL TRAIL DRUG   ( 20 
PATIENTS) 
 Mild Improvement in 2 (10%) cases 
 Moderate Improvement in 4 (20%) cases 
 Marked Improvement in 12 (60%) cases 
 Poor improvement in 2(10%) cases 
C.COMPARISION OF RESULTS 
PATIENTS TREATED WITH BOTH DRUG (20 Pts) AND  INTERNAL DRUG 
ALONE (20 Pts) 
Marked improvement occurs in administration of both drugs (70%) than internal 
drug alone (60%). 
Statistics Report : 
Since the P value is highly significant (<0.001). So there is 
significant reducing of VASI Score among the patients for the treatment of 
Venpulli (Vitiligo). Hence it is concluded that the treatment was effective and 
significant.   
P value for LFT & RFT is significant value. Hence the drug proves 
to be effective and significant.
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SUMMARY 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON   VENPULLI   
(VITILIGO)   WITH   SIDDHA TRIAL   DRUGS  “RASA CHENDHURAM” 
(INTERNAL) AND “PALAGARAI  KUZHAMBU” (EXTERNAL) has been 
choosen for the dissertation work by the author 
 The aim of the study was to evaluate the safety and and efficacy of siddha
drug rasa chendhuram (internal) and palagarai kuzhambu (external) in the
management of  venpulli (vitiligo).
 Various Literature evidences have been collected from siddha and modern
text books and also the drug review also said.
 Standared operative procedure for both trial drugs was standardized.
 Pre - clinical toxicity study was done for the trial drug rasa chendhuram in
using of Wister albino rats. Toxicity study was carried out after getting
proper permission in Institutional Animal Ethical Committee (IAEC).
 The study is conducted after the drug being screened by the screening
committee and the trial is also approved by the Institutional Ethical
Committee (IEC). The clinical trial also registered in Clinical Trial
Registry Of India(CTRI)
 Qualitative and Quantitative study on the trial drug such as Physico-
chemical analysis  had been done, result sare normal in range.
 40 Patients of both gender and in age group  between 18-60 years were
selected for  this clinical trial.
 All the details about this study and the trial Drug rasa chendhuram consent
forms duly signed by them, separate proforma was maintained for each
patients.
 Before starting the treatment, the blood samples of the selected patients
were subjected to investigation and photographs of the lesions were taken.
 From the first day onwards RASA CHENDHURAM ,  65 mg twice daily
was given internally  with honey and PALAGARAI KUZHAMBU  for
external application given to the patients.
 Diet  restrictions  were  strictly  imposed  during  the  treatment  period
especially foods  rich  in  Vit-c  should  be  avoided.
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 The patients  were  assessed  for  clinical improvement and adverse
effects during every visit. 
 Before starting the treatment and at the end of the treatment the
laboratory investigations were repeated.
 The photographs of the lesions were taken whenever necessary.
Photographs were also taken before and after the trial. The improvement 
was assessed by change in colour of the lesion, repigmentation and 
reduction in size of the lesion. 
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    CONCLUSION 
 
 
 
               The clinical study reveals the trial drugs showed marked improvement in 
65% of cases, Moderate improvement in 17.5% of cases, Mild improvement in 10 %   
of cases,  and   Poor improvement in 7.5% of case. 
 
               A toxicological study  in animal models reveals the safety and efficacy of 
the trial drug  Rasa chenduram. 
 
               Clinically, no adverse effects were reported during the trial and the 
laboratory investigations were also within normal limit. So, the drug is assumed to be 
safe for humans. 
 
               Hereby I conclude my study by reveals the effectiveness of the trial drugs 
“Rasa Chendhuram -  internal”  and  “Palagarai kuzhambu -  external”  are  effective  
in  producing  repigmentation and reducing the size of the hypopigmented patches in 
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the skin and hair “Venpulli noi” (Vitiligo  ). 
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GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI –  600 106.
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE  SIDDHA TRIAL DRUGS “RASA CHENDHURAM”
(INTERNAL) AND “PALAGARAI KUZHAMBU” (EXTERNAL)
FORM l - SCREENING & SELECTION PROFORMA
1.OP NO: ....................... 2. NAME: ………………………………………….
3. AGE: ………   4.GENDER: …… 5. OCCUPATION: ……………
6.INCOME:
7. ADDRESS:
 ……………………………………
……………………………………
……………………………………
8. CONTACT NO:    ……………………………………
INCLUSION CRITERIA
 Age :18-60 Yrs Yes/ No
 Sex : Both male and female Yes/ No
 Patients having symptoms of Depigmented patches without any structural
changes Yes / No
 Patients  are willing to give blood and urine for laboratory investigations
Yes / No
143
Patient willing to sign the informed consent stating that he/she will
conscientiously stick to the treatment during 48days but can opt out of the trial of
his/her  own conscious discretion  Yes / No
 Hypopigmentation due to worm infestation. Yes / No
EXCLUSION CRITERIA
HISTORY OF
1. Albinism Yes /No
2. Leprosy Yes /No
3. STD Yes /No
4. Depigmentation due to burns Yes /No
5. Pregnancy and Lactation Yes/No
6. Cardiac diseases Yes /No
7. HIV Yes /No
8. Patients with any other serious illness. Yes /No
9. History of long term use of steroids Yes/No
ADMITTED TO TRIAL
YES NO
Date:
Station:
Signature of the Guide: Signature of the Investigator:
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GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE EVALUATION OF SIDDHA TRIAL DRUG “RASA
CHENDHURAM” (INT) AND “PALAGARAI KUZHAMBU” (EXT)
 FORM II – HISTORY TAKING  PROFORMA
1. SERIAL NO OF THE CASE: ………………… 2.OP NO: ..........................
3. NAME: ……………………………  4. AGE: ………  5.GENDER: .................
6. OCCUPATION: ………………………………   7. INCOME: …………………..
 8. COMPLAINTS & DURATION:
7. HABITS OF
                        SMOKING, YES / NO If yes, specify duration ---------- yrs
                        TOBACCO, YES / NO If yes, specify duration ---------- yrs
                        ALCOHOL, YES / NO If yes, specify duration ---------- yrs
8. DRUG HISTORY:
9. FAMILY HISTORY:Whether this problem runs in family?  1. Yes  2.No
    If yes, mention the relationship of affected person(s)
1._________________  2._________________
10.DIETARY HABIT: 1.Vegetarian            2.Non-vegetarian
11. MENSTRUAL HISTORY:
Date:
Station:
Signature of the Investigator:                                              Signature of the Guide:
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GOVERNMENT   SIDDHA  MEDICAL  COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106.
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE EVALUATION OF SIDDHA TRIAL DRUG “RASA
CHENDHURAM” (INT) AND“PALAGARAI KUZHAMBU”(EXT)
FORM III – CLINICAL ASSESSMENT PROFORMA
1.OP NO: -----------  2.SERIAL  NO: ------
3. NAME: ----------------------        4. AGE: ---------              5.GENDER: ------
6. DATE OF INITIAL ASSESSMENT: ----------------------
7. GENERAL EXAMINATION:
1. Body weight [Kg] :
2. Height [cm] :
3. Body Temperature [F] :
4. Blood Pressure (mmHg) :
5. Pulse Rate /min. :
6. Heart Rate / min. :
7. Respiratory Rate /min. :
Yes            No
8. Pallor :
9. Jaundice :
10. Clubbing :
11. Cyanosis :
12. Pedal Oedema :
13. Lymphadenopathy  :
14. Jugular venous pulsation :
8. SYSTEMIC EXAMINATION:
Nervous system -----------------------
cardiovascular system ----------------------
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Uro-genital system -----------------------
Respiratory system ----------------------
Endocrine system -----------------------
Gastro intestinal system -------------------
9. SIDDHA SYSTEM OF EXAMINATION
1. THEGI (TYPE OF BODY CONSTITUTION):
1. Vatha udal
2. Pitha udal
 3. Kaba udal
 4. Thontha udal ------------------------
 2. NILAM:  [LAND WHERE PATIENT LIVED MOST]
1. Kurinji
2. Mullai
3. Marutham
4. Neithal
5. Paalai
3. KAALAM:
1. Kaar kaalam 4.Pinpani kaalam
2. Koothir kaalam 5. Ilavenil kaalam
3. Munpani kaalam 6.Muthuvenil kaalam
4. GUNAM:
1.Sathuvam 2.Raasatham 3.Thaamatham
5. PORI ,PULANGAL (SENSORY ORGANS):
Mei
Vaai
Kann
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Mooku
Sevi
6. KANMENDHIRIYAM (MOTOR ORGANS):
Kai
Kaal
Vaai
Eruvaai
Karuvaai
7. KOSANGAL (SHEATH):
Annamaya kosam
Pranamaya kosam
Manomaya kosam
Vignana maya kosam
Anandamaya kosam
8. UYIR THAATHUKKAL: [THREE HUMORS] (VALI, AZHAL,IYAM)
A) VALI
Praanan –--------------------
Abaanan --------------------
Samaanan ---------------------
Uthaanan ------------------------
Vyanan -------------------------
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Naagan ---------------------------
Koorman -----------------------------
Kirukaran ----------------------------
Devathathan ----------------------------
 Dhananjayan ----------------------------
B) AZHAL
Aamalakam --------------------
Ranjakam ---------------------
Saathakam -----------------------
Prasakam ------------------------
 Aalosakam --------------------------
C) IYAM
Avalambagam ------------------------
Kilethagam ---------------------------
Pothagam ------------------------------
Tharpagam ----------------------------
Santhigam -----------------------------
9.SEVEN UDAL DHATHUS: (7 SOMATIC COMPONENTS)
Saaram
Sennee
Oon
Kozhuppu
Enbu
Moolai
Sukkilam/Suronitham
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SIDDHA SYSTEM OF EXAMINATION
 1. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION]
 I. NAADI: [PULSE PERCEPTION]
 II .SPARISAM:
 III. NAA: [TONGUE]
 IV.NIRAM: [COMPLEXION]
1. Vadham        2. Pitham 3. Kabam
 V.MOZHI: [VOICE]
1. High Pitched
  2. Low Pitched
                       3. Medium Pitched
VI.VIZHI: [EYES]
VII. MALAM: [BOWEL HABITS / STOOLS]
Niram
Irugal
Ilagal
Others
 VIII. MOOTHIRAM [URINE EXAMINATION]
NEERKKURI:
Niram
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Manam
Edai
Nurai
Enjal
NEIKKURI
Date:
Station:
Signature of the Guide: Signature of the Investigator:
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GOVERNMENT SIDDHA MEDICAL COLLEGE
 ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE EVALUATION OF SIDDHA TRIAL DRUG “RASA
CHENDHURAM” (INT) AND “PALAGARAI KUZHAMBU” (EXT)
FORM lV -  CLINICAL ASSESSMENT DURING & AFTER TRIAL
1. OP  NO: …………  2. SL NO: ……    3.NAME: …………………………………
4. AGE: ………        5. GENDER: …...  6. DATE OF RECRUITMENT: ……………..
0th day 8th day 15th day 22th day
Site
Size of the lesions
Number of lesions
Borders
Itching
Depigmentation of Hair
New lesions appearance
Repigmentation of Hair
Colour change
 CentrifugalRegimentation
Centripetal
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Date:
Station:
Signature of the Guide                                                    Signature of the Investigator
29th day 36th day 43th day 49th day
Site
Size of the lesions
Number of lesions
Borders
Itching
Depigmentation of Hair
New lesions appearance
Repigmentation of Hair
Colour change
CentrifugalRepigmentation
Centripetal
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GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106.
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE EVALUATION OF SIDDHA TRIAL DRUG “RASA
CHENDHURAM” (INT) AND “PALAGARAI KUZHAMBU” (EXT)
FORM-V - LABORATORY INVESTIGATIONS
1. SERIAL NO OF THE CASE: …………………  2.OP   NO: ................................
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................
A) Blood Investigation
Blood Investigations Normal Values Before trmt(Date)
After trmt
(Date)
Hb (gm/dl) M:1215/W:11.5-14
T.WBC (cells/Cu.mm)
4000-11000
Polymorphs 40-75
Lymphocytes 20-40
Monocytes 2-10
Eosinophils 1-6
DIFFERENTIAL
COUNT (%)
Basophils 0-1
T.RBC(million cells/Cu.mm) M:4.0-5.5
  W:3.5-4.5
  ESR(mm/hour) ½ hr.
1 hr.
M:6-12
W:7-18
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Fasting    70-110Blood glucose
(mg/dl) PP    80-140
Blood urea    16-50
RFT (mg/dl) Serum
creatinine    0.6-1.2
Total bilirubin    0.2-1.2
Direct bilirubin    0.1-1.2
Indirect
bilirubin    0.2-0.7
SGOT    0-40
SGPT    0-35
LFT (mg/dl)
Alkaline
phosphatase    80-290
URINE INVESTIGATION
Urine investigation Before treatment After treatment
Albumin
Fasting sugar
PP sugar
Date:
Station:
Signature of the Guide:                                                     Signature of the Investigator
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GOVERNMENT SIDDHA MEDICAL COLLEGE
 ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE  EVALUATION  OF SIDDHA TRIAL DRUG
“RASA CHENDHURAM” (INT)  AND “PALAGARAI  KUZHAMBU”(EXT)
FORM VI-INFORMED CONSENT FORM
“I have read the foregoing information, or it has been read to me. I have
had the opportunity to ask questions about it and any questions I have asked have
been answered to my satisfaction.
            I   consent voluntarily to participate in this study and understand that I have
the   right to withdraw from the study at any time without in any way it affecting my
further medical care”.
"I have received a copy of the information sheet/consent form".
Date:
Signature of the participant
In case of illiterate participant
 “I have witnessed the accurate reading of the consent form to the potential
participant, and the individual has had the opportunity to ask questions. I confirm
that the individual has given consent freely.”
Date:
Signature of a witness       Left thumb Impression of the Participant
(Selected by the participant bearing no connection with the survey team)
Date:
Station:
Signature of participant:
 Signature of the Guide: Signature of the Investigator
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GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE EVALUATION OF SIDDHA TRIAL DRUG “RASA
CHENDHURAM” (INT) AND“PALAGARAI KUZHAMBU”(EXT)
FORM VII - WITHDRAWAL FORM
1. SERIAL NO OF THE CASE: …………………
2.OP  NO: ......................................
3. NAME: …………………………… 4.AGE: …………       5.GENDER: .............
6. DATE OF TRIAL COMMENCEMENT: ………………...
7. DATE OF WITHDRAWAL FROM TRIAL: ……………..
8. REASONS FOR WITHDRAWAL:
Long absence at reporting: Yes/ No
Irregular treatment: Yes/ No
Shift of locality: Yes/No
Increase in severity of symptoms: Yes/No
Development of severe adverse drug reactions: Yes/No
Date:
Station:
Signature of the Guide                                     Signature of the Investigator
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GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
                                                   CHENNAI – 600 106.
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE  EVALUATION  OF SIDDHA TRIAL DRUG
“RASA CHENDHURAM” (INT)  AND “PALAGARAI  KUZHAMBU” (EXT)
FORM VIII– PATIENT INFORMATION SHEET
Name of the principal Investigator: Dr.R.Kalaimani
Name of the institute: Government siddha medical college,
Arumbakkam
 Chennai - 106
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN
CLINICAL TRIAL.
I ,Dr . R.Kalaimani. studying MD (Siddha) at Government Siddha Medical College,
Chennai, is doing a trial on the study VENPULLI (VITILIGO). Vitiligo is a  common
persistent skin disease occurring through the world.
In this regard, I am in a need to ask you a few questions. I will maintain
confidentiality of your comments and data obtained. There will be no risk of
disclosing your identity and no physical, psychological or professional risk is
involved by taking part in this study.
Taking part in this study is voluntary. No compensation will be paid to you for taking
part in this study.
You can choose not to take part. You can choose not to answer a specific question.
There is no specific benefit for you if you take part in the study. However, taking part
in the study may be of benefit to the community, as it may help us to understand the
problem of defaulters and potential solutions.
            If you agree to be a participant in this study, you will be included in the study
primarily by signing the consent form and then you will be given the internal
medicine Rasa Chendhuram (Internal Medicine- 65 mg BD with palm jaggery for 48
160
days) and Palagarai Kuzhambu (External Medicine), assuring that you will not be
definitely hurt during the course of treatment.
            The information I am collecting in this study will remain confidential. I will
ask you few questions through a questionnaire. I will not write your name on this
form. I will use a code instead.
The questionnaire will take approximately 20 minutes of your time.
 If you wish to find out more about this study before taking part, you can ask
me all the questions you want or contact Dr.R.KALAI MANI , PG Scholar cum
principal investigator of this study, attached to Government siddha medical college,
Arumbakkam, Chennai – 106. You can also contact the Member-secretary of Ethics
committee, , Govt. Siddha Medical College, Chennai,
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GOVERNMENT SIDDHA MEDICAL COLLEGE
 ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
AN  OPEN  COMPARATIVE   CLINICAL  TRIAL  ON VENPULLI
(VITILIGO) WITH  THE  EVALUATION  OF SIDDHA TRIAL DRUG
“RASA CHENDHURAM” (INT)  AND “PALAGARAI  KUZHAMBU”(EXT)
FORM IX - ADVERSE REACTION FORM
SERIAL NO:
OP  NO:
NAME:
 AGE:
 GENDER:
DATE OF TRIAL COMMENCEMENT:
DATE OF OCCURRENCE OF THE ADVERSE REACTION:
TIME:
DESCRIPTION OF ADVERSEREACTION:
Date:
Station:
Signature of the Guide:                                                      Signature of the Investigator:
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